Xu v. FibroGen, Inc.

• Court: District Court, N.D. California
• Decided: July 15, 2022
• Docket: 3:21-cv-02623
• Status: Unknown

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 IN RE FIBROGEN, INC., SECURITIES Case No. 21-cv-02623-EMC LITIGATION. 8 ORDER DENYING DEFENDANTS’ 9 MOTION TO DISMISS 10 Docket Nos. 106-107, 109 11

12 13 14 I. INTRODUCTION 15 Plaintiffs filed this lawsuit against FibroGen and its current Chief Executive Officer 16 Enrique Conterno, former Interim Chief Executive Officer James Schoeneck, former Chief 17 Medical Officer K. Peony Yu1, current Chief Medical Officer Mark Eisner, and former Chief 18 Financial Officer Pat Cotroneo2 (collectively, “Individual Defendants”)3, for violations of Section 19 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 promulgated thereunder against 20 the Individual Defendants, for 96 allegedly false and misleading statements between December 20, 21 2018 and July 15, 2021 (the “Class Period”). 22 Plaintiffs filed this action on behalf of all investors who purchased or otherwise acquired 23

24 1 Dr. Yu was the Chief Medical Officer between April 2016 and December 20, 2020. CAC ¶ 23. She retired as CMO on December 20, 2020 but remained as an Executive Advisor until August 24, 25 2021. Id.

26 2 Cotroneo served as the Company’s CFO from 2008 to September 6, 2021, but remained as an Executive advisor until March 31, 2022. Id. ¶ 28. 27 1 FibroGen securities during the class period. According to Plaintiffs, Defendants falsely 2 represented the safety and efficacy data of its flagship drug, Roxadustat, and falsely assured 3 investors that the safety data was derived pursuant to FDA-sanctioned analysis. When the 4 deficiencies of the data were revealed, FibroGen’s stock price plummeted. 5 For the reasons set forth below, the Court DENIES Defendants’ motion to dismiss. 6 II. FACTUAL & PROCEDURAL BACKGROUND 7 A. Procedural & Factual Background 8 This action is a consolidation of a complaint filed by Plaintiff Peifa Xu in this Court and 9 other similar actions brought by purchasers of FibroGen securities elsewhere in this district.4 See 10 Docket No. 75. The amended consolidated class action complaint (“CAC”) was filed on April 12, 11 2021, as alleged below. 12 1. Defendants’ Representations 13 FibroGen is a biopharmaceutical company whose flagship drug, Roxadustat, is an 14 experimental pill that is designed to treat anemia in patients with chronic kidney disease (“CKD”). 15 Docket No. 97 (CAC) ¶ 4. The current standard of care to treat anemia in CKD patients, Epogen, 16 is only used in severe cases for patients already dependent on dialysis (“DD patients”) because it 17 leads to an increased risk of major adverse cardiac events (“MACE”). Id. at 3. Accordingly, the 18 key to securing critical FDA approval for Roxadustat was to demonstrate, through Phase 3 clinical 19 trial data, that Roxadustat was at least as effective as Epogen while avoiding the significant safety 20 issues that prevented Epogen from being used to treat incident DD patients and non-dialysis 21 dependent patients (“NDD patients”). Id. 22 Defendants repeatedly asserted that Roxadustat’s critical Phase 3 trial results showed that 23 the drug was superior to Epogen and safer than the placebo, which made FDA approval highly 24 compelling. Id. ¶ 5. The alleged false and misleading statements generally pertained to (1) 25 Roxadustat’s efficacy and safety, (2) whether Roxadustat would receive a “black box” (the FDA’s 26

27 4 Gutman v. FibroGen, Inc., No. 3:21-cv-02725-YGR; Grazioli v. FibroGen, No. 3:21-cv-03212- 1 most severe safety warning) label if approved, (3) the non-infringement margin FibroGen used in 2 its safety analysis, and (4) the expressions of optimism about Roxadustat’s potential and the 3 likelihood of FDA approval. Id.; see also Docket No. 91-2. 4 On the first day of the Class Period, December 20, 2018, FibroGen first released 5 Roxadustat’s Phase 3 trial data, and Yu emphasized that its results had “achieved superiority in 6 efficacy not only against placebo but also over [Epogen].” CAC ¶ 5. Such statements caused 7 FibroGen’s stock price to increase by over 46%, from $41.00 per share at the start of the Class 8 Period to a Class Period high of $59.91 per share on March 1, 2019. Id. ¶ 6. On May 9, 2019, 9 FibroGen released MACE safety data, and former CEO Neff highlighted that the results 10 demonstrated a “statistically significant advantage over [Epogen]” in the critical incident 11 dialysis group. Id. ¶ 5. Conterno also made statements regarding the drug’s safety, such as that 12 “the data [was] extremely clean from my perspective when it comes to cardiovascular safety” 13 and that “we showed a 30% reduction in MACE risk” for incident dialysis patients, which 14 differentiated Roxadustat from its competition. Id. He also stated that “there’s no warrant [for 15 a] Black Box” warning—the “strongest warning the FDA can mandate for prescription drugs”— 16 due to the “compelling” cardiovascular safety data. Id. ¶¶ 5, 40. Yu also “set Roxadustat up to be 17 the first anemia drug to avoid a Black Box warning[.]” Id. ¶ 5. Defendants reaffirmed these 18 results throughout the end of the Class Period. Id. 19 Furthermore, in a conference call with analysts and investors following a pre-NDA 20 meeting between FDA and FibroGen in July 2019, Neff announced that FibroGen had “reached 21 an agreement with the [FDA] on the content of the NDA including the cardiovascular safety 22 analysis[.]” Id. ¶ 167. Yu also reaffirmed that “Phase 3 results confirmed the cardiovascular 23 safety of Roxadustat.” Id. 24 In November 2019, “FibroGen issued a press release announcing ‘Positive Phase 3 Pooled 25 Roxadustat Safety and Efficacy Results’” based on nine studies. Id. ¶ 171. The press release 26 specifically stated that Roxadustat “demonstrate[d] a cardiovascular safety profile comparable 27 with placebo in patients not on dialysis, and comparable or in some cases better than that of 1 epoetin alfa5 in patients on dialysis” by reducing “risk of MACE by 30% and MACE+ by 2 34% compared to [Epogen]” in the crucial incident dialysis population.” Id. 3 Leading up to FibroGen’s submission of the Roxadustat Drug Application (“NDA”) with 4 the U.S. Food and Drug Administration (“FDA”) on December 23, 2019, FibroGen’s stock price 5 again surged by over 22%, from $37.01 on November 4, 2019, to $45.30 on December 20, 2019. 6 Id. ¶¶ 65–66. 7 2. Defendants’ Gains 8 AstraZeneca funded the development and eventual FDA approval of Roxadustat. Id. ¶ 38. 9 FibroGen’s “[p]otential milestone payments” under its agreement with AstraZeneca totaled $1.2 10 billion—$571 million for “development and regulatory milestones” and $652.5 million for 11 “commercial-based milestones”—and could reach as high as $1.6 billion. Id. ¶ 44. FibroGen had 12 stated that its revenue during the Class Period was “generated primarily from our collaboration 13 agreements . . . for the development and commercialization of Roxadustat[.]” Id. For example, 14 the submission of the Roxadustat NDA to the FDA on December 23, 2019 triggered a milestone 15 payment from AstraZeneca amounting to $50 million, which comprised approximately 20% of the 16 Company’s annual revenues for 2019. Id. ¶ 66. 17 Plaintiffs allege that the Individual Defendants took advantage of FibroGen’s inflated stock 18 prices by engaging in insider trading that yielded them proceeds of over $42 million. Id. ¶¶ 135– 19 39. Moreover, the Individual Defendants received compensation awards, including bonuses and 20 awards of stock options worth tens of millions of dollars, which were directly tied to FibroGen 21 meeting regulatory and commercial milestones with respect to Roxadustat. Id. 22 3. Disclosures and Consequences 23 According to Plaintiffs, Defendants’ fraud began to unravel when Yu announced his 24 sudden retirement on November 27, 2020. Id. ¶ 72. Three weeks later, on December 18, 2020, 25 FibroGen issued a press release that the FDA extended review of the drug by three months. Id. ¶ 26 73. Then on March 1, 2021, FibroGen announced that the FDA would hold an Advisory 27 1 Committee (“AdCom”) meeting to review Roxadustat’s NDA, which was a surprising setback late 2 in the FDA approval timeline. Id. at 5. On this news, FibroGen’s stock price fell $16.18 per 3 share, or over 32%, to close at $34.35 per share. Id. On April 6, 2021, FibroGen provided 4 “clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the 5 roxadustat Phase 3 program” through a press release. Id. ¶ 265. In the press release, FibroGen 6 admitted that its management became aware of “post-hoc changes to the stratification factors6” in 7 Roxadustat’s Phase 3 trial results—which allegedly amounted to a manipulation of all nine key 8 analyses after the data had been fully unblinded—and that they needed to clarify this with the 9 FDA. Id. at 2, 4, 5. Based on the actual “prespecified” FDA analyses, FibroGen could not 10 “conclude that Roxadustat reduced the risk of MACE… or is superior to … [Epogen.]” Id. ¶ 8. 11 The press release states in part:

12 “As members of senior management were preparing for the upcoming FDA Advisory Committee meeting, we became aware 13 that the primary cardiovascular safety analyses included post-hoc changes to the stratification factors,” said Enrique Conterno, 14 Chief Executive Officer, FibroGen. “While all of the analyses set forth below, including the differences in the stratification factors, 15 were included in the NDA, we promptly decided to clarify this issue with the FDA and communicate with the scientific and 16 investment communities.”

17 Mr. Conterno continued, “It is important to emphasize that this does not impact our conclusion regarding the comparability, with 18 respect to cardiovascular safety, of roxadustat to epoetin-alfa in dialysis-dependent (DD) patients and to placebo in non-dialysis 19 dependent (NDD) patients. We continue to have confidence in roxadustat’s benefit risk profile.” 20 . . . 21 Pooled Cardiovascular Safety Data 22 As previously disclosed, the Company agreed with the FDA in the 23 pre-NDA meeting that the primary analysis in non-dialysis would be ITT (intention to treat with long-term follow up) and in dialysis 24 would be OT-7 (on-treatment plus 7 days). MACE, a composite endpoint of all-cause mortality, stroke, and myocardial infarction, 25 was the primary safety endpoint agreed on with the FDA. The table below describes the cardiovascular safety results using the post-hoc 26 stratification factors reported at the American Society of 27 Nephrology conference in November 2019, as well as the analyses 1 with the prespecified stratification factors which have not been previously publicly reported. 2 . . . 3 As reflected in the table, the analyses with the pre-specified 4 stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals. For MACE+ in dialysis 5 and for MACE and MACE+ in incident dialysis, the 95% confidence intervals include 1.0. While these hazard ratios remain 6 below 1.0, based on these analyses we cannot conclude that roxadustat reduces the risk of (or is superior to) MACE+ in 7 dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa. These analyses do not change the Company’s 8 assessment that roxadustat is comparable to placebo in nondialysis dependent patients and to epoetin-alfa in dialysis dependent patients 9 using MACE to measure cardiovascular safety. 10 Docket No. 111, Exhibit PP (April 6, 2021 Press Release). 11 Once Defendants’ post-hoc manipulations were corrected, the true data revealed that there 12 were substantial safety concerns—including increased risk of serious afflictions such as 13 thrombosis, seizures, stroke, and even death—that it showed the drug was significantly less 14 effective and less safe than placebo or even Epogen, which already carried the “Black Box” 15 warning. CAC ¶ 7. As a result, Roxadustat’s true data failed to support FDA approval in any 16 patient population at all, effectively dooming its FDA approval prospects. Id. FibroGen’s share 17 price dropped almost in half in two days, from $34.64 per share on April 6, 2021 to $18.81 per 18 share on April 8, 2021. Id. ¶ 8. 19 4. FDA and Market Response 20 According to Plaintiffs, the FDA had referred to this type of practice as after-the-fact 21 “data-dredging” done in an “attempt to elicit a positive result from a failed study[.]” Id. ¶ 79. 22 Since then, numerous market analysts, nephrologists, and news sources condemned FibroGen. Id. 23 at ¶¶ 10, 97– 101 (“[t]he re-statement reduced the benefit from [Roxadustat] vs controls in every 24 case [and] erased the appearance of superiority over [Epogen] in incident dialysis patients”; “the 25 fact that [Roxadustat’s] Incident Dialysis is no longer ‘statistically’ superior – is a material change 26 to the profile and [removed] one of the key prior advantages”; “the worst case of data 27 manipulation in years[,]”’; “[t]he fact that all nine analyses across the patient groups looked less 1 carefully selected the new criteria to make roxa’s profile look better”; “This deeply damages the 2 reputation of FibroGen . . . I feel very misled, and I don’t think there is any excuse for this. I don’t 3 know how this could happen accidentally.”). Even then, Defendants failed to reveal other 4 prespecified FDA analyses—known as “sensitivity” analyses—that revealed that Roxadustat’s 5 safety issues were so significant that the drug could not be approved at all. Id. ¶ 11. 6 On July 15, 2021, the FDA’s AdCom met to review Roxadustat’s NDA and unequivocally 7 concluded that FibroGen’s own undisclosed, prespecified sensitivity analyses demonstrated that 8 the drug’s efficacy over Epogen was inconclusive at best. Id. With regard to safety, the drug 9 caused “greater rates of some important adverse events [] than even [Epogen],” including a higher 10 rate of death and other major side effects. Id. Thus, the AdCom voted virtually unanimously 11 against approval for Roxadustat for any patient population, even with a “Black Box” warning. Id. 12 The following day, the FibroGen’s stock price plummeted over 42%, or $10.49 per share, from 13 $24.84 per share to $14.35 per share on July 16, 2021. In sum, FibroGen’s stock price lost 75% of 14 its value in a few short months due to the alleged data manipulation and never recovered. CAC ¶ 15 13. 16 III. LEGAL STANDARD 17 A. Motion to Dismiss 18 Federal Rule of Civil Procedure 8(a)(2) requires a complaint to include “a short and plain 19 statement of the claim showing that the pleader is entitled to relief.” Fed. R. Civ. P. 8(a)(2). A 20 complaint that fails to meet this standard may be dismissed pursuant to Rule 12(b)(6). See Fed. R. 21 Civ. P. 12(b)(6). To overcome a Fed. R. Civ. P. 12(b)(6) motion to dismiss after the Supreme 22 Court’s decisions in Ashcroft v. Iqbal, 556 U.S. 662 (2009) and Bell Atlantic Corporation v. 23 Twombly, 550 U.S. 544 (2007), a plaintiff’s “factual allegations [in the complaint] ‘must . . . 24 suggest that the claim has at least a plausible chance of success.’” Levitt v. Yelp! Inc., 765 F.3d 25 1123, 1135 (9th Cir. 2014). The court “accept[s] factual allegations in the complaint as true and 26 construe[s] the pleadings in the light most favorable to the nonmoving party.” Manzarek v. St. 27 Paul Fire & Marine Ins. Co., 519 F.3d 1025, 1031 (9th Cir. 2008). But “allegations in a 1 allegations of underlying facts to give fair notice and to enable the opposing party to defend itself 2 effectively.” Levitt, 765 F.3d at 1135 (quoting Eclectic Props. E., LLC v. Marcus & Millichap 3 Co., 751 F.3d 990, 996 (9th Cir. 2014)). “A claim has facial plausibility when the Plaintiff pleads 4 factual content that allows the court to draw the reasonable inference that the Defendant is liable 5 for the misconduct alleged.” Iqbal, 556 U.S. at 678. “The plausibility standard is not akin to a 6 ‘probability requirement,’ but it asks for more than a sheer possibility that a defendant has acted 7 unlawfully.” Id. (quoting Twombly, 550 U.S. at 556). 8 The doctrine of incorporation by reference is distinct from judicial notice. The doctrine 9 “permits a district court to consider documents ‘whose contents are alleged in a complaint and 10 whose authenticity no party questions, but which are not physically attached to the . . . 11 pleadings.’” In re Silicon Graphics Sec. Litig., 183 F.3d 970, 986 (9th Cir. 1999) (quoting Branch 12 v. Tunnell, 14 F.3d 449, 454 (9th Cir.1994)). The court may incorporate such a document “if the 13 plaintiff refers extensively to the document or the document forms the basis of the plaintiff's 14 claim.” United States v. Ritchie, 342 F.3d 903, 908 (9th Cir. 2003). 15 B. Securities Fraud Pleading 16 Rule 10b-5, which implements the anti-fraud provisions of section 10(b) of the Securities 17 Exchange Act, makes it “unlawful for any person, directly or indirectly, by the use of any means 18 or instrumentality of interstate commerce, or of the mails or of any facility of any national 19 securities exchange . . . [t]o make any untrue statement of a material fact or to omit to state a 20 material fact necessary in order to make the statements made, in the light of the circumstances 21 under which they were made, not misleading.” 17 C.F.R. § 240.10b-5. To state a claim for 22 securities fraud, a complaint must allege:

23 (1) a material misrepresentation or omission by the defendant; (2) scienter; 24 (3) a connection between the misrepresentation or omission and the purchase or sale of a security; 25 (4) reliance upon the misrepresentation or omission; (5) economic loss; and 26 (6) loss causation. 27 Halliburton Co. v. Erica P. John Fund, Inc., 134 S.Ct. 2398, 2407 (2014) (citations omitted). heightened pleading requirements of Rule 9(b) and the Private 1 Securities Litigation Reform Act (“PSLRA”). Police Ret. Sys. v. Intuitive Surgical, Inc., 759 F.3d 1051, 1057–58 (9th Cir. 2014). 2 “Due in large part to the enactment of the [PSLRA], plaintiffs in private securities fraud class actions face formidable pleading 3 requirements to properly state a claim and avoid dismissal[.]” Metzler Inv. GMBH v. Corinthian Colls., Inc., 540 F.3d 1049, 1054– 4 55 (9th Cir. 2008). To satisfy these requirements, a complaint must: (i) “specify each statement alleged to have been misleading, the 5 reason or reasons why the statement is misleading, and, if an allegation regarding the statement or omission is made on 6 information and belief ... state with particularity all facts on which that belief is formed,” 15 U.S.C. § 78u-4(b)(1)(B); and (ii) “state 7 with particularity facts giving rise to a strong inference that the defendant acted with the required state of mind,” or scienter, id. § 8 78u-4(b)(2). 9 Habelt, et al., Plaintiffs, v. iRythm Technologies, Inc., et al., No. 21-CV-00776-EMC, 2022 WL 10 971580, at *6–7 (N.D. Cal. Mar. 31, 2022). “[F]alsity and scienter in private securities fraud cases 11 are generally strongly inferred from the same set of facts, and the two requirements may be 12 combined into a unitary inquiry under the PSLRA.” In re Daou Sys., Inc., 411 F.3d 1006, 1015 13 (9th Cir. 2005) (citation and internal quotation marks omitted). 14 IV. DISCUSSION 15 A. Judicial Notice and Incorporation by Reference 16 Defendants seek to introduce various documents related to the alleged statements, and 17 Plaintiffs do not dispute the introduction of these documents. The Court may take judicial notice 18 of Exhibits A–D, F, H, Q, WW, and ZZ-EEE because they are publicly available information, 19 including FibroGen’s public filings with the SEC, publicly available documents published by the 20 FDA or submitted to the FDA, available on publicly available websites affiliated with a 21 government agency, or publicly available press releases from FibroGen’s partners. See Lee, 250 22 F.3d at 690; Perkins, 53 F. Supp. 3d at 1204. Exhibits E, G, I–P, R–VV, and XX–YY may be 23 incorporated by reference. The doctrine of incorporation “permits a district court to consider 24 documents ‘whose contents are alleged in a complaint and whose authenticity no party questions, 25 but which are not physically attached to the . . . pleadings.’” In re Silicon Graphics Sec. Litig., 26 183 F.3d 970, 986 (9th Cir. 1999) (quoting Branch v. Tunnell, 14 F.3d 449, 454 (9th Cir.1994)). 27 The court may incorporate such a document “if the plaintiff refers extensively to the document or 1 (9th Cir. 2003). In this case, Plaintiffs either refer to their contents or quote portions of the 2 documents to support their claims and allegations, thereby forming the basis for Plaintiff’s claims. 3 See Ritchie, 342 F.3d at 908; Daniels-Hall v. National Educ. Ass’n, 629 F.3d 992, 998 (9th Cir. 4 2010) (“Plaintiff directly quoted the material . . . thereby incorporating [the material] into the 5 Complaint.”). 6 B. Securities Fraud 7 To plausibly allege securities fraud, Plaintiffs must allege with particularity “each 8 statement alleged to have been misleading, the reason or reasons why the statement is misleading,” 9 and “facts giving rise to a strong inference that the defendant acted with the required state of 10 mind.” Habelt, 2022 WL 971580, at *6–7. 11 1. Safe Harbor and Forward-Looking Statements 12 The PSLRA's safe harbor provision allows exemptions for certain forward-looking 13 statements. See 15 U.S.C. § 78u-5(c). “The PSLRA's safe harbor is designed to protect 14 companies and their officials from suit when optimistic projections of growth in revenues and 15 earnings are not borne out by events.” In re Quality Sys., Inc. Sec. Litig., 865 F.3d 1130, 1142 16 (9th Cir. 2017). To qualify for protection, the statements must be either: (1) “forward-looking 17 statements that are identified as a forward-looking statement and . . . accompanied by meaningful 18 cautionary statements identifying important factors that could cause actual results to differ 19 materially from those in the forward-looking statement” or (2) forward-looking statements that 20 were not “made with actual knowledge . . . that the statement was false or misleading.” Id. §§ 21 78u-5(c)(1)(A)(i), (c)(1)(B).

22 Where a statement is “mixed,” i.e., contains both forward-looking and non-forward-looking elements, and where a plaintiff alleges the 23 entire statement is misleading because it omitted material information, the court should determine whether the statement as a 24 whole, not a particular part, is misleading. See Ivax, 182 F.3d at 806 (“If the allegation is that the [whole] statement is misleading, then it 25 makes no sense to slice the [statement] into separate sentences.”).

26 The “doctrine reflects nothing more than ‘the unremarkable proposition that statements must be analyzed in context.’” Fecht, 70 27 F.3d at 1082 (9th Cir.1995) (internal citations omitted). It “is thus only when reasonable minds could not disagree as to whether the 1 mix of information in the document is misleading.” Id. 2 In re Immune Response Sec. Litig., 375 F. Supp. 2d 983, 1033 (S.D. Cal. 2005). 3 A forward-looking statement is:

4 (A) a statement containing a projection of revenues, income (including income loss), earnings (including earnings loss) per 5 share, capital expenditures, dividends, capital structure, or other financial items; 6 (B) a statement of the plans and objectives of management for future 7 operations, including plans or objectives relating to the products or services of the issuer; 8 (C) a statement of future economic performance, including any such 9 statement contained in a discussion and analysis of financial condition by the management or in the results of operations 10 included pursuant to the rules and regulations of the Commission; 11 (D) any statement of the assumptions underlying or relating to any 12 statement described in subparagraph (A), (B), or (C);

13 (E) any report issued by an outside reviewer retained by an issuer, to the extent that the report assesses a forward-looking statement 14 made by the issuer; or

15 (F) a statement containing a projection or estimate of such other items as may be specified by rule or regulation of the [Securities 16 and Exchange] Commission. 17 15 U.S.C.A. § 78u-5(i)(1). 18 a. Forward-Looking Statements 19 Defendants argue that certain statements are forward-looking and therefore not actionable 20 under the PSLRA’s safe harbor.7 See Docket No. 107 (Defs. Mot.) at 20. These include 21 statements about (1) the potential approval of the NDA, (2) what label the FDA might require for 22 Roxadustat if approved, and (3) Roxadustat’s potential. Id. Plaintiffs argue that statements such 23 as Roxadustat “met the safety standards”; “based on what we have seen, we are pretty comfortable 24 with safety”; and “we had all the guidance from the FDA we needed to put together a winning 25 7 Dr. Yu also argues that her words in the CAC were selectively presented, taking them out of 26 context to make them sound “misleadingly suggest certainty and guaranteed outcomes rather than her actual forward-looking optimism accompanied by appropriate cautionary remarks.” Yu Reply 27 at 11. The Court has reviewed the text of Yu’s statements and finds that it is not meaningfully 1 submission”—are misstatements of past or current fact, and thus ineligible for safe harbor 2 protection. Docket No. 114 (Opp’n) at 27. 3 Further analysis of the listed statements demonstrates that there are elements within them 4 that are not forward-looking. “To the extent that [Defendants] highlights [clinical trial] results that 5 were already available at the time, such statements are not forward-looking and therefore are not 6 eligible for such safe harbor protection.” In re Immune, 375 F. Supp. 2d at 1034. Here, the 7 alleged statements are based on existing and allegedly manipulated data. Statement #1 is such an 8 example:

9 We are excited to have achieved superiority in efficacy not only against placebo but also over epoetin alfa in our studies… [t]hese 10 results support [R]oxadustat’s potential to bring clinical benefit over current standard of care, such as reducing blood transfusion risk in 11 patients on dialysis and those not on dialysis, and to improve patient access to anemia therapy with a new convenient oral therapeutic. 12 13 See Docket No. 107-1 (Statement Chart), Statement #1; see also Statement # 63 (“[Regarding the 14 NDD analyses] Roxadustat ‘has the right efficacy safety profile to be able to have a really good 15 uptake in the NDD setting and be able to be a catalyst for the overall expansion of that market’”). 16 The “potential” of Roxadustat is based on the assertions that existing clinical studies achieved 17 superiority in efficacy against both placebo and epoetin, which are not forward-looking. 18 Statements about the potential approval of the NDA are similarly based on existing data. 19 For example, Defendants characterize Statement #5, which emphasizes “positive . . . results” that 20 “support [FibroGen’s] NDA[,]” as forward-looking. Defs. Mot. at 20; Statement Chart, Statement 21 #5. However, the full text makes clear that the statement was based on the clinical data:

22 “In these 5 U.S. ROW studies, we enrolled a total of 7,721 patients composed of 3,917 in dialysis and 3,804 in non-dialysis. All of 23 these studies have positive top line results. We and our partners believe the results from these trials to support our NDA [to the 24 FDA] as well as our marketing authorization application, or MAA, to the European Medicines Authority, or EMA. The fully 25 adjudicated MACE results, including completing adjudication procedures to enable consistent safety assessment without bias, are 26 to be included in our planned NDA to the FDA. Completion of the full adjudication procedures is on track for the second quarter 27 of 2019. discussions with counterpart teams at AZ and Astellas and 1 discussions with our partners' leadership there is a strong conviction to move ahead to file the NDA and MAA this year.” 2 3 Statement Chart, Statement #5 (emphasis added); see also Statement #11 (“[T]hese positive safety 4 data give us confidence as we progress in preparation for the U.S. NDA.”). 5 Furthermore, statements are not forward-looking if they “refer to past interactions with the 6 [FDA], and do not merely express optimism or confidence about FDA approval.” In re MannKind 7 Sec. Actions, 835 F. Supp. 2d 797, 816–17 (C.D. Cal. 2011) (finding that the statement “meeting 8 [with the FDA] . . . seemed to be very supportive” was not forward-looking”). Statements that 9 FibroGen had a “very good pre-NDA meeting with the FDA on [R]oxadustat[,]” that the FDA 10 reached an agreement “on our proposed pooled MACE analysis[,]” and that FibroGen was “very 11 pleased with the agreement [with the FDA] on the primary safety analysis of our primary 12 cardiovascular safety endpoint in NDD” are not mere expressions of optimism that would qualify 13 for safe harbor protection. Statement #25–27. They are based on past interactions with the FDA. 14 Statements about favorable labeling similarly highlight the existing clinical trial analyses. 15 See, e.g., Statement #51 (“I feel it basically shows that the product is safe because of the safety 16 profile when it comes to CV comparable to placebo . . . [I]n [DD], when it comes to incident 17 dialysis, we do show an actual significant benefit, well, with a 30% reduction in MACE . . . When 18 I put those two reasons together, look at the compelling nature of our data, and I feel that . . . 19 there’s no warrant [for a] Black Box . . .”; Statement #42 (“we have the optionality of an upside of 20 not being able to get [a black box], given the data that we have”). These statements about 21 Roxadustat’s potential, approval, and labeling cannot be meaningfully separated from the 22 allegedly manipulated clinical analyses and past interactions with the FDA. Statements that mix 23 past or current facts with forward-looking optimistic statements do not qualify for safe harbor 24 protection. (“[A] defendant may not transform non-forward-looking statements into forward- 25 looking statements that are protected by the safe harbor provisions of the PSLRA by combining 26 non-forward-looking statements about past or current facts with forward-looking statements about 27 projected revenues and earnings.”). In re Quality Sys, 865 F.3d at 1141. The statements at issue 1 alleged statements are not forward-looking and does not qualify for safe harbor protection, the 2 Court need not discuss whether the statements were accompanied by meaningful cautionary 3 language. 4 b. Actual Knowledge 5 Defendants also argue that the alleged statements are also protected under the second 6 prong of the safe harbor, as Plaintiffs fail to allege that Defendants had “actual knowledge” that 7 any statement was false or misleading when made. Docket No. 115 (Defs. Reply) at 20 (citing 8 Intuitive Surgical, 759 F.3d at 1058; 15 U.S.C. § 78u-5(c)(1)(B); In re Splash Tech. Holdings, Inc. 9 Sec. Litig., 160 F. Supp. 2d 1059, 1070 n.5 (N.D. Cal. 2001)). However, this argument is 10 unconvincing because the allegation that the Defendants manipulated the clinical data to obtain 11 more favorable analyses implies knowledge. See Opp’n at 28. 12 2. Opinions and Puffery 13 Under securities law, “[s]tatements of mere corporate puffery, vague statements of 14 optimism like ‘good,’ ‘well-regarded,’ or other feel good monikers, are not actionable because 15 professional investors, and most amateur investors as well, know how to devalue the optimism of 16 corporate executives.” Police Ret. Sys. of St. Louis v. Intuitive Surgical, Inc., 759 F.3d 1051, 1060 17 (9th Cir. 2014) (internal quotation marks and citation omitted). “A statement is considered 18 puffery if the claim is extremely unlikely to induce . . . reliance. Ultimately, the difference 19 between a statement of fact and mere puffery rests in the specificity or generality of the claim.” 20 Newcal Indus., Inc. v. Ikon Off. Sol., 513 F.3d 1038, 1053 (9th Cir. 2008). 21 As for opinions, there are “three different standards for pleading falsity of opinion 22 statements” in the Ninth Circuit. City of Dearborn Heights Act 345 Police & Fire Ret. Sys. v. 23 Align Tech., Inc., 856 F.3d 605, 615 (9th Cir. 2017).

24 First, when a plaintiff argues there are material misrepresentations, she must “allege both that the speaker did not hold the belief she 25 professed and that the belief is objectively untrue.” Second, when a plaintiff “relies on a theory that a statement of fact contained within 26 an opinion statement is materially misleading, the plaintiff must allege that the supporting fact the speaker supplied is untrue.” The 27 third theory relates to omissions, which are not relevant to this 1 In re QuantumScape Sec. Class Action Litig., No. 3:21-CV-00058-WHO, 2022 WL 137729, at 2 *15 (N.D. Cal. Jan. 14, 2022) (citations omitted) (quoting Align Tech., 856 F.3d at 615). 3 Defendants argue that the alleged statements constitute corporate optimism, on which 4 “investors do not rely.” Defs. Mot. at 19 (citing Kovtun v. VIVUS, Inc., 2012 WL 4477647, at *11 5 (N.D. Cal. Sept. 27, 2012)); see generally Docket No. 109 (Yu Mot.). This includes statements 6 that: the data and interaction with the FDA were “positive,” “good,” “favorable,” “right,” 7 “encouraging,” “extremely clean,” “excellent,” “robust,” “reassuring,” or “strong,” the NDA 8 submission was “complete,” the Company found the safety data “compelling,” and felt 9 “comfortable,” “confident,” “excited,” “pleased,” or “good” about it. Id. at 19–20 (citing In re 10 Copper Mountain Sec. Litig., 311 F. Supp. 2d 857, 869 (N.D. Cal. 2004) (statements that results 11 were “very positive” or the company had a “strong” product “constitute run-of-the-mill corporate 12 optimism on which no reasonable investor would rely”); Jasin v. VIVUS, Inc., 721 F. App’x 665, 13 667–68 (9th Cir. 2018) (approval “looking good” was a “mildly optimistic, subjective assessment” 14 insufficient to plead fraud). 15 Furthermore, Defendants contend that statements that a product had an “excellent” or 16 “compelling” risk/benefit profile are opinions that “inherently reflect the speaker’s assessment of 17 and judgment about the underlying circumstances.” Id. (citing Markette v. XOMA Corp., 2017 18 WL 4310759, at *4 (N.D. Cal. 2017); In re LifeLock, Inc. Sec. Litig., 690 F. App’x 947, 951 (9th 19 Cir. 2017) (what defendants “believe[d]” or “fe[lt]” are opinions). Defendants argue that all 20 statements interpreting the safety data were opinions and were framed as beliefs rather than 21 objective conclusions and that any interpretations of data are essentially opinions. Id. at 14 22 (quoting Statement Chart, Statement #23 (“we believe our MACE results in dialysis and in non- 23 dialysis also support the conclusion of no increased cardiovascular safety risk”) (emphasis in 24 original)). Therefore, Defendants point out that Plaintiffs fail to allege the opinions were not 25 genuine. According to Defendants, “[FibroGen’s] disclosures about the pooled safety analyses 26 cannot form the basis of a fraud claim unless the CAC pleads with particularity that the statements 27 were not ‘sincerely held.’” Defs. Reply at 17 (quoting In re Sanofi-Aventis Sec. Litig., 774 F. 1 It is true that “[w]hen valuing corporations, ... investors do not rely on vague statements of 2 optimism like ‘good,’ ‘well-regarded,’ or other feel good monikers.” In re Cutera Sec. Litig., 610 3 F.3d 1103, 1111 (9th Cir. 2010). However, this Court has previously explained:

4 “When determining whether statements amounted only to puffery, the court must analyze the context in which the statements were 5 made.” Even a statement of opinion or an expression of corporate optimism may be deemed actionable in certain circumstances 6 because “there is a difference between enthusiastic statements amounting to general puffery and opinion-based statements that are 7 anchored in ‘misrepresentations of existing facts.’” As the Ninth Circuit stated in Casella v. Webb, 883 F.2d 805, 808 (9th Cir.1989), 8 “What might be innocuous ‘puffery’ or mere statement of opinion standing alone may be actionable as an integral part of a 9 representation of material fact when used to emphasize and induce reliance upon such a representation.” Accordingly, the Court may 10 not assess the statements listed in the FAC in a vacuum, “plucking the statements out of their context to determine whether the words, 11 taken per se, are sufficiently ‘vague’ so as to constitute puffery,” but rather will examine the entire statement and its circumstances to 12 determine if it is actionable. 13 Mulligan v. Impax Lab'ys, Inc., 36 F. Supp. 3d 942, 966 (N.D. Cal. 2014) (citations omitted). This 14 Court then further explained:

15 To be sure, the statements include superlatives which are indicative of the speaker's opinion and are often seen in “puffing” statements— 16 for example, references to “significant” manufacturing and quality control improvements. However, as the Court found above in its 17 discussion over whether these statements are “forward-looking,” the vast majority of the statements identified in the FAC contain 18 factual representations at their core—that Defendants had responded to the FDA Warning Letter by instituting various changes 19 to the manufacturing and/or quality control procedures or processes. Similarly, that certain statements are predicated with indications 20 that the speaker “thought” or “believed” a given statement does not change this result. 21 22 Id. at 967 (citations omitted). 23 Likewise, in this case, Defendants’ expressions of confidence are in the context of 24 discussing the safety analyses of the existing data. For example, after describing the efficiency 25 and safety as “robust,” Yu described that Roxadustat-treated patients had lower transfusion risk 26 than epoetin and lowered MACE+ risk in the dialysis patient pool. See Statement #44. Similarly, 27 the descriptions “positive,” “good,” “favorable,” and “right” for the safety profiles were later 1 reduced cardiovascular outcomes in [the incident dialysis] population.” Statements #63, 65. The 2 CAC is replete with such objective statements, “such as claims that Roxadustat ‘reduced risk of 3 MACE by 30%’ in the crucial incident dialysis population; and that the analyses were ‘agreed 4 [upon] with the FDA.’” CAC ¶¶ 158, 167, 171. 5 Yu’s statements are similarly premised on facts such as “Roxadustat was at least non- 6 inferior to epoetin alfa even in the conversion stable dialysis patients” and “we had already talked 7 with the FDA about [the] analytical plan, and we had made the agreement on the analysis plan . . . 8 and the numbers I had just presented, were based on the agreed upon analysis plan that we have 9 made with the FDA.”8 Statements #18, 35. Yu argues that it is a stretch to assume in hindsight 10 that her statements referenced the allegedly manipulated stratification factors and not the specific 11 analytical methods actually discussed at the pre-NDA meeting in July 2019. See Docket No. 116 12 (Yu Reply) at 14. However, “the numbers [that Yu] had just presented[,]” seem to have pertained 13 to the analyses containing the post-hoc changes. See CAC ¶ 27. As such, investors may have 14 reasonably equated the “analytical plan” with analyses containing the alleged post-hoc changes. 15 Like statements about safety, Plaintiffs argue that Defendants overstated Roxadustat’s 16 efficacy by claiming that Roxadustat had “achieved superiority in efficacy not only against 17 placebo but also over [Epogen],” and had “efficacy benefits” including “patients had a 33% 18 reduction in the risk of blood transfusion compared to epoetin [alfa]” and “improvement in quality 19 of life.” Opp’n at 23 (citing CAC ¶¶ 148, 163, 187, 189, 190). Plaintiffs argue that Defendants 20 were not permitted under the federal securities laws to make glowing statements about 21 Roxadustat’s superior efficacy while concealing numerous significant safety issues that wholly 22 eclipsed any such claims. Id. (citing Oklahoma Police Pension & Ret. Sys. v. LifeLock, Inc., 780 23 F. App’x 480, 483 (9th Cir. 2019) (“companies mislead investors when they tout their products’ 24 capabilities but fail to disclose significant flaws that undercut those capabilities”); Khoja v. 25 Orexigen Therapeutics, Inc., 899 F.3d 988, 1010 (9th Cir. 2018) (“once [the Company] chose to 26 tout the apparently positive [] results, [the Company] had the obligation also to disclose that they 27 1 were likely unreliable”)). Defendants, while allegedly concealing the fact that Roxadustat was 2 significantly less safe than placebo and even Epogen, touted Roxadustat’s efficacy. Opp’n at 23. 3 Plaintiffs allege that in reality, the FDA determined that the claimed reduction in blood 4 transfusions versus Epogen was “unclear” and likely nonexistent at the untested lower doses—and 5 the AdCom found there was “a surprising lack of improvement in quality of life” in patients taking 6 Roxadustat. Id. (citing CAC ¶¶ 104, 112, 146, 191, 194). 7 Defendants argue that Plaintiffs conflate efficacy with the FDA’s risk-benefit analysis, 8 which assesses whether the benefits (efficacy) of a product warrant its risk (safety). Defs. Mot. at 9 14. According to Defendants, it is not wrong that a drug is effective and also has side effects. 10 Defs. Reply at 15. Therefore, issues with safety do not render statements about efficacy false.9 Id. 11 According to Defendants, the FDA had confirmed the contrary–that “[R]oxadustat’s efficacy is 12 not in question” as “[a]ll studies . . . demonstrated efficacy.” Defs. Mot. at 14 (citing Ex. VV 13 (FDA Brief to AdCom) at 7); Yu Mot. at 4 (citing same). 14 At the hearing, parties clarified that efficacy and safety are inevitably intertwined because 15 the key to efficacy is safe dosing levels. While Defendants contend that Roxadustat’s efficacy was 16 demonstrated, Plaintiffs have alleged that the claimed reduction in blood transfusions was unlikely 17 at lower doses. CAC ¶¶ 104, 112, 146, 191, 194. As such, statements of efficacy may 18 nevertheless have been false and misleading if they were based on unreasonably high dosing 19 levels. In short, Plaintiffs have alleged a plausible claim of falsity that are not mere opinions and 20 puffery. 21 Finally, Defendants point out that mere disagreements with the type of analysis used and 22 the interpretation of a clinical trial result cannot be false and misleading. See Defs. Mot. at 18 23 (citing In re MELA Scis., Inc. Sec. Litig., No. 10 CV 8774 VB, 2012 WL 4466604, at *13 24 (S.D.N.Y. Sept. 19, 2012); DeMarco v. DepoTech Corp., 149 F. Supp. 2d 1212, 1225 (S.D. Cal. 25 9 Defendants also cite Kovtun, 2012 WL 4477647, *9 to argue that issues with safety do not render 26 statements about the separate concept of efficacy false. Defs. Reply at 15. Defendants incorrectly attempt to argue that this Court previously rejected a plaintiff’s attempt to challenge statements 27 regarding efficacy by identifying safety risks. However, this Court simply found that there was no 1 2001)). However, what Plaintiffs allege goes beyond merely using different statistical analyses 2 and differences in interpreting the results of the clinical trial; the crux of the complaint is that 3 Defendants actively manipulated the data post-hoc. See CAC ¶ 247 (Defendants “submitted the 4 true prespecified analyses to the FDA in the Roxadustat NDA, but never publicly disclosed them, 5 and instead attempted to pass off their ‘post-hoc’ manipulated data to investors as the real data for 6 over two years”). 7 However, general statements not premised on factual misrepresentations, such as: “there is 8 a strong conviction to move ahead to file the NDA and MAA this year,” “we have a high level of 9 conviction on the overall submission, the strength of our data,” “walking out of [a meeting with 10 the FDA after the NDA submission], we felt that we had all the guidance from the FDA we 11 needed,” that “interaction with the FDA was positive” are not based on facts but on Defendants’ 12 personal impressions. Statement Chart, Statement # 34, 57; Defs. Yu Reply at 13. Therefore, 13 Statements #5, 34, 57, 60, 67, and 73 are opinions that cannot be objectively untrue. 14 In sum, with the exception of some general statements about how the NDA meeting felt to 15 FibroGen and Defendants’ confidence in the NDA submission, other statements about the safety 16 and efficacy of Roxadustat and the potential for NDA approval are not mere puffery or opinions 17 and, therefore, actionable. 18 3. Pleading Falsity with Particularity 19 “Falsity is alleged when a plaintiff points to defendant's statements that directly contradict 20 what the defendant knew at that time.” Khoja, 899 F.3d at 1008. See In re Twitter, Inc. Sec. 21 Litig., No. 19-CV-07149-YGR, 2020 WL 7260479 (N.D. Cal. Dec. 10, 2020), aff'd sub nom. 22 Weston Fam. P'ship LLLP v. Twitter, Inc., 29 F.4th 611 (9th Cir. 2022) (“[P]laintiffs . . . fail to 23 suggest that defendants’ statements directly contradicted what they plausibly knew at the time and 24 were therefore false.”). The quote from Khoja has not been explained by the Ninth Circuit. See 25 Weston Fam. P'ship LLLP v. Twitter, Inc., 29 F.4th 611, 619 (9th Cir. 2022). But courts in this 26 district have elaborate on this language when discussing falsity:

27 The cases plaintiffs cite in support of its omission theory are particularity under an omissions theory precisely because defendants 1 in those cases were already in possession of information that directly contradicted their public statements when made. See Khoja, 899 2 F.3d at 1008 (“Falsity is alleged when a plaintiff points to defendant’s statements that directly contradict what the defendant 3 knew at that time.”).

4 In Khoja, for example, defendants were touting positive interim results of a study without also disclosing that the FDA had already 5 explicitly warned defendants that these same results had “a high degree of uncertainty” and were therefore unreliable. . . . Contrast 6 this with the alleged omissions here, where plaintiffs have brought forth no facts to show defendants knew the NDA was destined for 7 rejection in light of their alleged failure to reference 6-and 9-month toxicology studies. 8 9 Immanuel Lake v. Zogenix, Inc., No. 19-CV-01975-RS, 2020 WL 3820424, at *9 (N.D. Cal. Jan. 10 27, 2020). “Even if a statement is not false, it may be misleading if it omits material information.” 11 Id. at 1008–09. 12 For affirmative representations, “to properly allege falsity, a securities fraud complaint 13 must now specify each statement alleged to have been misleading, the reason or reasons why the 14 statement is misleading, and, if an allegation regarding the statement or omission is made on 15 information and belief, state with particularity all facts on which that belief is formed.” In re Rigel 16 Pharms., Inc. Sec. Litig., 697 F.3d 869, 877 (9th Cir. 2012) (internal quotation marks, citation, and 17 alteration omitted). For omissions, “it must affirmatively create an impression of a state of affairs 18 that differs in a material way from the one that actually exists.” Brody v. Transitional Hosps. 19 Corp., 280 F.3d 997, 1006 (9th Cir. 2002). The securities laws “do not create an affirmative duty 20 to disclose any and all material information. Disclosure is required under these provisions only 21 when necessary to make statements made, in the light of the circumstances under which they were 22 made, not misleading.” Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27, 44, 131 S.Ct. 1309, 23 179 L.Ed.2d 398 (2011) (internal quotation marks, citation, and alteration omitted). 24 First, Defendants argue that the CAC fails to plead falsity because it simply does not allege 25 that any data was falsified or that any individual defendant did not sincerely believe that they were 26 reasonable interpretations of the data. Defs. Reply at 19; Defs. Mot. at 15. However, the CAC 27 alleges that Defendants had “manipulated” Roxadustat’s clinical trial data, and such post-hoc 1 of data analysis). CAC ¶ 79, n.3; Opp’n at 15. The allegations of manipulation imply that the data 2 was falsified and that Defendants knew so. 3 Defendants next argue that it was not misleading for FibroGen to share its interpretation of 4 the data based on only certain analyses submitted in the NDA because there is no “affirmative 5 duty to disclose any and all material information.” Defs. Mot. at 17, n.15 (quoting In re Rigel, 697 6 F.3d at 880 n.8 (“[A] company is not required to disclose every safety-related result from a clinical 7 trial, even if the company discloses some safety-related results and even if investors would 8 consider the omitted information significant.”)). This argument also fails because Plaintiffs’ 9 allegation is not that Defendants simply omitted some information but that analyses were 10 manipulated to show a reduction in MACE risk when there was no evidence of it. 11 Defendants also argue that allegations must specifically challenge either the accuracy of 12 the numbers contained in the analyses or the conclusions drawn from them. Defs. Mot. at 17 13 (quoting In re Regulus Therapeutics Inc. Sec. Litig., 406 F. Supp. 3d 845, 857 (S.D. Cal. 2019) 14 (dismissing claims where the plaintiff offered only “vague and impressionistic . . . allegations 15 regarding the contradictory . . . results purportedly held by Defendants”)). According to 16 Defendants, the CAC pleads no facts that demonstrate that the underlying clinical data did not 17 support the results that FibroGen disclosed. Id. at 17–18. However, Plaintiffs sufficiently 18 challenge with specificity the facts and conclusions drawn from the clinical trial data by 19 Defendants. For example, they allege that “contrary to Defendants’ statements above highlighting 20 the purported statistically significant 30% and 34% reduction in MACE and MACE+ risk in the 21 crucial incident dialysis population—under Roxadustat’s true, undisclosed prespecified analyses, 22 there was no evidence of any purported reduction of MACE risk in this population at all.” CAC ¶ 23 191. 24 As such, Defendants’ general arguments fail. Arguments regarding specific allegations are 25 discussed below. 26 a. The Pre-NDA Meeting 27 Regarding any alleged statements falsely representing an agreement with the FDA, 1 about the analytical framework for the pooled safety analyses until the pre-NDA meeting in July 2 2019. Defs. Mot. at 15–16 (citing Ex. J at 6 (“[W]e have not yet spoken with the FDA. . . . 3 [T]here is a discussion planned with the FDA about these various analyses.”)). Therefore, any 4 such statements could not have been false. FibroGen did not purportedly follow the “analyses 5 required by the FDA” as no such analyses existed until after the statements were made. Id. In 6 fact, the analytical framework was developed with the FDA post-hoc. Id. at 18. 7 However, this fact does not create a meaningful difference. Plaintiffs do not allege that 8 Defendants claimed that the framework for their analyses was approved by the FDA prior to July 9 2019. Rather, Plaintiffs assert that the alleged manipulations themselves were misleading. As 10 such, Defendant’s argument is a moot point. Opp’n at 17–18 (arguing that the data they showed in 11 May 2019, prior to the pre-NDA meeting, was manipulated data because they used the post-hoc 12 stratification factors rather than the “prespecified” factors). Any discussion of the “agreement” 13 with the FDA postdates July 2019. 14 b. The April 6, 2021 Press Release 15 The April 6 press release states in part:

16 “As members of senior management were preparing for the upcoming FDA Advisory Committee meeting, we became aware 17 that the primary cardiovascular safety analyses included post- hoc changes to the stratification factors,” said Enrique Conterno, 18 Chief Executive Officer, FibroGen. “While all of the analyses set forth below, including the differences in the stratification factors, 19 were included in the NDA, we promptly decided to clarify this issue with the FDA and communicate with the scientific and 20 investment communities.” Mr. Conterno continued, “It is important to emphasize that this does 21 not impact our conclusion regarding the comparability, with respect to cardiovascular safety, of roxadustat to epoetin-alfa in 22 dialysis-dependent (DD) patients and to placebo in non-dialysis dependent (NDD) patients. We continue to have confidence in 23 roxadustat’s benefit risk profile.”

24 FibroGen continues to prepare for the FDA Advisory Committee meeting and will work closely with the FDA to bring this important 25 new treatment to patients living with anemia of CKD.

26 There is no change in the underlying roxadustat data, or to the efficacy analyses from the Phase 3 program. The Company has 27 begun a comprehensive internal review to ensure such issues do not 1 April 6, 2021 Press Release. 2 The press release also included the following chart comparing the figures for the post-hoc 3 stratification factors with the unreported pre-specified stratification factors: 4 Analyses with post-hoc stratification Analyses with pre-specified 5 factors stratification factors HR (95% Confidence Interval) HR (95% Confidence Interval) 6 Non Dialysis (OLYMPUS, ANDES, ALPS N=4,270); ITT 7 MACE 1.08 (0.94, 1.24) 1.10 (0.96, 1.27) MACE+ 1.04 (0.91, 1.18) 1.07 (0.94, 1.21) 8 ACM 1.06 (0.91, 1.23) 1.08 (0.93, 1.26) Dialysis Dependent (HIMALAYAS, SIERRAS, ROCKIES N=3,880); OT-7 9 MACE 0.96 (0.82, 1.13) 1.02 (0.88, 1.20) MACE+ 0.86 (0.74, 0.98) 0.91 (0.80, 1.05) 10 ACM 0.96 (0.79, 1.17) 1.02 (0.84, 1.23) 1 Incident Dialysis (N=1,526); OT-7 MACE 0.70 (0.51, 0.96) 0.82 (0.60, 1.11) a 12 MACE+ 0.66 (0.50, 0.89) 0.78 (0.59, 1.02) ACM 0.76 (0.52, 1.11) 0.82 (0.57, 1.18)

| a.

IS According to Plaintiffs, Defendants’ April 6 press release was an admission that they YI

a 16 manipulated the clinical trial results by making “post-hoc changes to the stratification factors.”

vo 17 Opp’n at 15-16. Defendants dispute Plaintiffs’ characterization that the April 6 press release

18 || constitutes an admission because (1) there was “no change in the underlying Roxadustat data, or to 19 Il the efficacy analyses from the Phase 3 program” and (2) the submission to the FDA expressly 20 contemplated that the data would be analyzed using both study-specific (1.e., “pre-specified”) and 21 “other common” stratification factors. Defs. Reply at 16; Yu Reply at 3. Furthermore, FibroGen 22 || told investors throughout the Class Period that it would be analyzing the data in many ways. Id. 23 As such, Investors could not have been misled into thinking that there was only one way to 24 analyze the data or that FibroGen had not conducted any other analyses. /d. Defendants argue 25 || that the fact that new management decided on a different set of analyses does not make the 26 previously shared information false. Defs. Reply at 17. Yu also points out that in May 2019, 27 when the data was unblinded, FibroGen had told the public that there were some issues in the 28 || NDD studies that would be discussed with the FDA at the pre-NDA meeting and that after the pre-

1 DNA meeting, FibroGen had come to an agreement with the FDA about this issue.10 Yu Reply at 2 4. 3 However, although the press release does not seem to be an explicit admission that 4 Defendants manipulated the data, it constitutes an admission at least to the extent that they made 5 “post-hoc changes to the stratification factors.” April 6, 2021 Press Release. According to 6 Plaintiffs, these changes were so significant that FibroGen needed to promptly “clarify this issue 7 with the FDA” to “make sure that it was clear which analyses used which factors, prespecified and 8 post-hoc” in 2021. Opp’n at 15–16 (quoting CAC ¶ 8). The press release admitted that “based on 9 these [unmanipulated FDA prespecified] analyses we cannot conclude that Roxadustat reduces the 10 risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis 11 compared to [epoetin-alfa].” April 6, 2021 Press Release. According to Plaintiffs, “investors had 12 been completely unaware of this material information, as Roxadustat’s true FDA-prespecified data 13 ‘[had] not been previously publicly reported.’” Opp’n at 15–16. These alleged facts suggest that 14 the post-hoc changes (eventually admitted to on April 6) were material, undisclosed facts to both 15 the FDA and investors prior thereto and support an inference of falsity. 16 c. Impact of the Post-Hoc Changes 17 Defendants argue that the alleged statements were not false because FibroGen reiterated in 18 the April 2021 release the same conclusions regarding comparative MACE risk in the NDD and 19 DD trials. Defs. Mot. at 17. Although the MACE risk disclosed on April 6 differed slightly from 20 those disclosed before, the additional analyses did not change the conclusion that there was no 21 clinically meaningful difference in risk of MACE between Roxadustat, Epogen, and placebo. Id. 22 Defendants further point out that the FDA also concluded that there was “no significant difference 23 in the risk of MACE” between the drug and its comparators and that “[t]he findings were 24 qualitatively similar, regardless of the stratification factors.”11 Id. (citing Docket No. 111, Ex. XX 25 10 Yu also points out that she stepped down as FibroGen’s CMO in December 2020, prior to this 26 April 6, 2021 press release. Yu Reply at 3. However, considering that the press release constitutes an admission by FibroGen that post-hoc changes were made while Yu was still at 27 FibroGen, Yu’s involvement in the manipulation of the analyses is still plausibly alleged. 1 at 169–71; FDA Brief to AdCom at 47); Yu Reply (citing same). Plaintiffs respond that FDA 2 never agreed that there was no significant difference in the risk of MACE between the drug and its 3 comparators in NDD and DD patients. Opp’n at 18. 4 Although statements that Defendants cite indicate that the post-hoc changes may not have 5 made a large difference, they do not show that the FDA concluded that there was no difference in 6 MACE risk. Defendants cite an FDA Briefing Document prepared on July 14, 2021 for the 7 advisory meeting held on July 15, 2021. See FDA Brief to AdCom at 1 (“The MACE meta- 8 analysis included pre-specified, trial-specific stratification factors. The applicant also provided 9 results using common stratification factors defined post[-]hoc. The findings were qualitatively 10 similar, regardless of the stratification factors.”). However, a Briefing Document is not a 11 conclusive result, especially when the AdCom allegedly “overwhelmingly” voted against the drug. 12 See Opp’n at 19. Plaintiffs assert a plausible claim of falsity. 13 Defendants also refer to a record of the actual FDA advisory committee meeting. See 14 Defs. Mot. at 17. Although Defendants selectively quote the portion that there was “no significant 15 difference in the risk of MACE” for the NDD population, Dr. Unger subsequently stated that there 16 was an increased risk of MACE in other studies. See id. Dr. Ellis Unger’s remarks state in part:

17 In summary, there was considerable difference between the estimated hazard ratios for the primary on-study analysis and the 18 OT-plus-7 sensitivity analysis. In the NDD population, the treatment policy analysis results suggest no significant 19 difference in the risk of MACE relative to placebo. On the other hand, the results from the on-treatment or the OT-plus-7 20 analysis suggest an increased risk of MACE for the roxadustat arm compared to placebo. In summary, in the DD population, 21 results suggested no significant difference in the risk of MACE while subjects were receiving the assigned treatment. However, the 22 on-study analysis suggests an increased risk of MACE relative to ESA, and the direction of such risk was also consistent in a trial that 23 was not considered for meta-analysis. 24 Docket No. 111, Ex. XX at 169–71. Furthermore, Plaintiffs allege that this manipulation was so 25 material that Defendants had to retract their submission to a medical journal. Opp’n at 15–16 26 (citing CAC ¶¶ 84–85). Accordingly, Plaintiffs have plausibly alleged that the post-hoc 27 1 manipulations were material. 2 d. Significance of Post-hoc 3 Parties also dispute the significance of “post-hoc changes to the stratification factors” 4 admitted in the April 6, 2021 press release. Defendants argue that a focus on “post-hoc” is a red 5 herring because the entire analytical framework was “post-hoc,” based upon agreement with the 6 FDA at the July 9, 2019 pre-NDA meeting. Defs. Mot. at 7. FibroGen also never commented on 7 the stratification factors to be used in the analyses. Defs. Reply at 13. 8 Plaintiffs have sufficiently alleged that the deviations from the prespecified stratification 9 factors were improper post-hoc changes. According to Plaintiffs, the statistical plans for the trials 10 were submitted to the FDA in August and September 2018, before the Phase 3 data were 11 unblinded and well before the July 2019 pre-NDA meeting. Opp’n at 18. The purpose of the pre- 12 NDA meeting was not to decide on a brand-new statistical analysis of the data and change the 13 fully unblinded results of the prespecified analyses post-hoc, but to determine which of these 14 prespecified plans (the “ITT” or “OT+7” analyses) would be used as the primary analyses for the 15 NDA. Id. at 18, n.9. Both analyses were to be conducted pursuant to prespecified stratification 16 factors without manipulations. Id. These facts are sufficient to plausibly allege that the post-hoc 17 changes were improper. 18 e. The Non-Inferiority Margin 19 Plaintiffs allege that Yu and Conterno (and non-defendant Neff) falsely implied to 20 investors that the FDA had agreed to a non-inferiority margin of 1.3 for the pooled safety analyses 21 because they referred to it as a “standard,” “reference,” or “commonly applied” margin12. Opp’n 22 at 19–20. Based on this margin, Defendants “falsely stated that Roxadustat had achieved 23 noninferiority because its hazard ratio was below this 1.3 threshold which the FDA would 24 supposedly be looking for in reviewing Roxadustat’s MACE results.” Id. This was allegedly 25 12 The goal of the safety trials was to show that Roxadustat was “non-inferior” relative to Epogen 26 or placebo, meaning that Roxadustat did not cause more adverse safety events compared to them. CAC ¶ 47. This was measured by hazard ratios—the smaller the hazard ratio, the safer the drug. 27 Id. ¶ 48. The non-inferiority margin is the threshold below which it can be established that the 1 misleading because the FDA had already expressly rejected 1.3 non-inferiority margin for the 2 reason that “it was defined [by FibroGen] after the results of the study were known” – i.e., post- 3 hoc. Opp’n at 20; CAC ¶¶ 55, 110, 152. Instead, the FDA had told FibroGen that it “had a goal of 4 1.25” during the pre-NDA meetings, as confirmed by Dr. Farrell, who was personally involved in 5 the negotiations. Opp’n at 20–21 (quoting In re MannKind, 835 F. Supp. 2d at 809–10 6 (statements “that the FDA had accepted, or blessed, or agreed to the Defendants’ [] 7 methodology— which are shown to be false by a later revelation demonstrating that the FDA had 8 not, in fact, done any such thing—do not constitute ‘fraud-by-hindsight’”)). 9 Plaintiffs’ allegations are plausible only to the extent that the CAC alleges that data was 10 manipulated to show a lower margin, but not to the extent that Defendants falsely implied to 11 investors that the FDA had agreed to a non-inferiority margin of 1.3. This is because none of the 12 relevant alleged statements imply an agreement with the FDA regarding the non-inferiority 13 margin:

14 • FibroGen stated that the “ITT [intention-to treat]” method was “among the several statistical methods that we will discuss with the FDA,” and 15 that “[i]n these analyses, Roxadustat was comparable based on a commonly applied non-inferiority margin of 1.3.” Statement #9. 16 • . . . in response to analyst questions, Neff stated that the Company felt 17 the ITT results were what “describe[ed] the situation most effectively,” and asserted that an upper bound on the hazard ratio of 1.3 under the 18 ITT analysis was the “safety evaluation standard the FDA usually asks for.” Statement #19. 19 • Yu stated that FibroGen was “using the conventional standards of 20 noninferiority, which is widely published for assessment of CKD anemia and have previously been used by [the FDA] for assessment of 21 cardiovascular safety in similar types of composite endpoints … that standard has been 1.3 for upper bound of 95% confidence interval. If 22 we use that standard, the answer is yes, we have achieved non- inferiority.” Statement #20. 23 • FibroGen: The press release expressly clarified that for NDD patients, 24 the results were based on the “ITT analysis agreed with the FDA” and that the “[r]isks of MACE, MACE+, and all-cause mortality in 25 Roxadustat patients were comparable to placebo in the ITT analyses based on a reference non-inferiority margin of 1.3.” Statements #32, 38. 26 • The 10-Q added that in FibroGen’s “pre-NDA meeting, the FDA agreed 27 that the ITT analysis would be our primary cardiovascular safety account for the higher drop-out rate in the placebo arm. The figure 1 below shows that in the 4,270 pooled non-dialysis patients (OLYMPUS, ANDES, and ALPS), the risk of MACE, MACE+, and all-cause 2 mortality in Roxadustat patients were comparable to that in placebo patients based on a reference non-inferiority margin of 1.3.” Statements 3 #38, 45.

4 • Conterno: In response to another analyst inquiry regarding whether the upper bound of the confidence intervals that was pre-agreed with the 5 FDA was 1.25 or 1.3 for noninferiority, Conterno stated that “in non- dialysis, we basically show comparability relative to placebo. With 6 regards to the 1 point to any measures of excess risk, you mentioned 1.25 or 1.3, I think I said in a number of different occasions that we do 7 not have a pre-agreed noninferiority margin with the FDA.” Statement #84. 8 9 The words “reference,” “standard,” “conventional,” and “usually” do not imply any 10 certainty; therefore, merely referencing a commonly applied standard does not indicate falsity. In 11 fact, Conterno made clear that there was no noninferiority margin agreement with the FDA. 12 Statement #84 (“I think I said in a number of different occasions that we do not have a pre-agreed 13 noninferiority margin with the FDA.”). Neff’s full statement similarly shows that no such 14 agreement was made:

15 [E]ven though these maybe aren’t the measures that will ultimately be the ones that are evaluated, they are an ultimate 16 safety evaluation standard the FDA usually asks for whether you pose it or not. So everybody felt like this is something that's very 17 descriptive and very informative. I would hesitate to do anything else beyond talking about the ITT results because we do not 18 have a specific agreement with FDA on method of analysis. And as such, it’s a little presumptuous. 19 20 Statement # 19. Statements #9 and #32 point out that Defendants agreed on an ITT analysis with 21 the FDA but refer to the non-inferiority margin as merely “commonly applied” and “reference . . . 22 margin.” See Statements #9, 32, 38. 23 Nevertheless, allegations that data was manipulated to conform to these margins survive. 24 For example, Plaintiff’s allegation that Defendants’ post-hoc manipulation of the analysis in the 25 NDD group “resulted in an upper bound hazard ratio for the key MACE and ACM endpoints of 26 1.24 and 1.23, respectively—i.e., below the 1.25 goal—when the actual FDA prespecified analysis 27 exceeded 1.25”—is still relevant. CAC ¶ 83. Defendants argue that it makes no sense that 1 presented using the “post-hoc” stratification factors were below 1.25 anyway. Defs. Reply at 15. 2 This argument fails; while the post-hoc manipulated analysis did not reach 1.25, CAC ¶ 55, the 3 prespecified sensitivity analyses (that FibroGen never disclosed to investors and were disclosed by 4 the FDA for the first time during the AdCom) exceeded both the 1.25 and 1.3 margins. CAC ¶¶ 5 175, 183, 204, 228. As such, there was sufficient reason for FibroGen to lie about the 1.25 figure. 6 As such, the CAC survives to the extent that Defendants represented that the hazard ratios fell 7 below 1.3 when it, in fact, allegedly exceeded 1.3. See id. 8 4. Scienter 9 A complaint alleging securities fraud under § 10(b) must state with particularity facts 10 giving rise to a strong inference that the defendant acted with scienter. See 15 U.S.C. § 78u- 11 4(b)(2)(A); Tellabs, Inc. v. Makor Issues & Rts., Ltd., 551 U.S. 308, 321 (2007). Scienter is “a 12 mental state embracing intent to deceive, manipulate, or defraud.” Tellabs, 551 U.S. at 308; see 13 also Metzler, 540 F.3d at 1061. “To adequately demonstrate that the defendant acted with the 14 required state of mind, a complaint must allege that the defendants made false or misleading 15 statements either intentionally or with deliberate recklessness.” Zucco Partners, LLC v. Digimarc 16 Corp., 552 F.3d 981, 991 (9th Cir. 2009) (quotation marks and citation omitted). “[A] court must 17 consider plausible, nonculpable explanations for the defendant's conduct, as well as inferences 18 favoring the plaintiff.” Tellabs, 551 U.S. at 308. “[A]n inference of scienter must be more than 19 merely plausible or reasonable—it must be cogent and at least as compelling as any opposing 20 inference of nonfraudulent intent.” Id. at 314. “The inference that the defendant acted with 21 scienter need not be irrefutable, i.e., of the ‘smoking-gun’ genre, or even the ‘most plausible of 22 competing inferences.’” Id. at 324. Unlike falsity, “The Supreme Court has emphasized that 23 courts ‘must review all the allegations holistically’ when determining whether scienter has been 24 sufficiently pled. The relevant inquiry is ‘whether all of the facts alleged, taken collectively, give 25 rise to a strong inference of scienter, not whether any individual allegation, scrutinized in 26 isolation, meets that standard.’” Reese v. Malone, 747 F.3d 557, 569 (9th Cir. 2014) (citing 27 Tellabs, 551 U.S. at 323). 1 Arena and Endologix. In Arena, the Ninth Circuit held that alleged statements were sufficiently 2 indicative of scienter:

3 Contrary to Arena’s representations to investors, it was not true that the “preclinical, animal studies” demonstrated the “long- 4 term safety and efficacy” of lorcaserin or “the potential risk that [it] may be toxic or cause cancer in humans.” It was also not true 5 that Arena had “all of the data in hand” or that “everything that [they had] compiled so far” was “favorable.” These statements were 6 representations about lorcaserin that Arena could not, in fact, support at the time they were made. Arena was free to express 7 confidence in FDA approval. It might have represented that Arena was working through some requests from the FDA and was 8 confident the data would vindicate lorcaserin. But what it could not do was express confidence by claiming that all of the data 9 was running in lorcaserin’s favor. 10 Schueneman v. Arena Pharms., Inc., 840 F.3d 698, 708 (9th Cir. 2016). 11 The Ninth Circuit reached a different conclusion in Endologix. There, the defendants 12 assured investors that the FDA would likely approve its device despite reports of safety issues in 13 Europe. See Nguyen v. Endologix, Inc., 962 F.3d 405, 408–11 (9th Cir. 2020). Later, the 14 company revealed that the FDA had “questions” but stated that the situation was “very easy” to 15 remedy. Id. at 412. In the end, the FDA did not approve the device on the timeline the defendant 16 represented, but the Ninth Circuit held that there was not an adequately strong inference of 17 scienter to be drawn. Id. at 416, 419. The Ninth Circuit noted the implausibility of the plaintiff’s 18 theory and noted that the initial U.S. data was more promising than the European data:

19 [W]hy would defendants promise the market that the FDA would approve Nellix if defendants knew the FDA would eventually figure 20 out that Nellix could not be approved due to “intractable” and “unresolvable” device migration problems? The theory does not 21 make a whole lot of sense. It depends on the supposition that defendants would rather keep the stock price high for a time and 22 then face the inevitable fallout once Nellix's “unsolvable” migration problem was revealed. 23 . . .

24 Underpinning the Fourth Circuit's reasoning in Cozzarelli was the point we recognize here: “[i]t is improbable that [a company] 25 would stake its existence on a drug and a clinical trial that the company thought was doomed to failure.” Id. at 627. The 26 plaintiffs’ “inference of fraud based on the supposed impossibility of [a successful trial] [wa]s thus not even plausible, much less 27 convincing.” Id. This was so in Cozzarelli even though the City of Edinburgh Council v. Pfizer, Inc., 754 F.3d 159, 170 (3d Cir. 1 2014) (affirming dismissal of securities fraud complaint because, inter alia, “the initiation of Phase 3 cost millions of dollars and 2 required FDA approval, rendering it improbable that defendants would have continued if they did not believe their 3 interpretation of the interim results or if they thought the drug a complete failure”). 4 5 Id. at 415–16. The Ninth Circuit also noted that during the first year, the defendants had favorable 6 studies. Id. at 419. Then, in the second year, the defendants “disclosed that information and 7 expressed their belief that the issue could be addressed with a narrowed IFU[.]” Id. Therefore, the 8 Ninth Circuit found important that the plaintiff failed to identify sufficient factual basis as to why 9 defendants could not have believed that a revised IFU would allow the FDA to approve the 10 product. Id. 11 a. Plausibility of Scienter Given Post-Hoc Changes 12 Defendants rely on Endologix to argue that Plaintiffs’ theory has already been rejected as 13 nonsensical by the Ninth Circuit. Defs. Mot. at 22 (citing Endologix, 962 F.3d at 415; Patel v. 14 Seattle Genetics, Inc., 2018 WL 2359137, at *9 (W.D. Wash. May 24, 2018) (finding no scienter 15 where defendants “cooperat[ed] with the FDA” and “expended significant time and money to 16 develop” drug while adverse events would “inevitably” be discovered and drug would “be shut 17 down”)). According to Defendants, Plaintiffs’ allegations are unavailing for the same reason that 18 it makes no sense that a company would conspire to artificially inflate the Company’s stock price 19 even though they knew the truth would eventually come out during the FDA’s review of the 20 Roxadustat NDA and face an inevitable fall out.13 Defendants point out that Plaintiffs have not 21 excluded the possibility that their analyses were “the honest analysis and conclusions of their 22 authors.” Defs. Reply at 8. Furthermore, given the drug’s approval in Europe, it was not 23 unreasonable for defendants to believe in their product. Id. 24 Defendants also find similarities to AstraZeneca Securities Litigation, 559 F. Supp. 2d 453 25

26 13 Defendants also argue that it does not make sense that FibroGen would have colluded with its development partner, AstraZeneca. Id. However, this argument fails because Plaintiffs allege that 27 AstraZeneca was also deceived by FibroGen because FibroGen was eligible to receive up to $875 1 (S.D.N.Y. 2008). Defs. Reply at 8. The AstraZeneca defendants similarly failed to disclose a 2 safety issue. AstraZeneca, 559 F. Supp. 2d at 458, 463. Later, the AdCom voted to recommend 3 against approval, and the FDA declined to approve the FDA. Id. There, the court found that it 4 was not unreasonable for the defendants to believe in their product, given among other facts, that 5 the drug was approved in Europe. Id. at 471. The court also noted that “there [was] nothing 6 whatever to indicate that the statements made did not reflect the honest belief of the authors” such 7 as any red flags, and that “[i]t [was] impossible to read the FDA document and the AstraZeneca 8 document without concluding that both present the honest analysis and conclusions of their 9 authors.” Id. 10 This case is closer to Arena than AstraZeneca and Endologix. First, the Ninth Circuit 11 distinguished AstraZeneca in Arena:

12 Defendants contend that this case is really just like AstraZeneca: a good-faith scientific disagreement between the FDA and Arena 13 about the meaning of the Rat Study and support for the Prolactin Hypothesis. If it were simply the case that this dispute turned on 14 whether scienter could exist based on the reasonableness of Arena’s interpretation of the Rat Study versus the FDA’s interpretation, there 15 would be little question Defendants would have the better argument. See AstraZeneca, 559 F.Supp.2d at 471 (“As of the time when the 16 FDA Advisory Committee met ..., AstraZeneca had its side of the case and the FDA staff had its side. The FDA staff view prevailed 17 before the Advisory Committee. This does not mean that AstraZeneca was not conscientious in advocating the drug ... before 18 the FDA, nor does it mean that the information issued publicly over the course of more than a year was dishonest or recklessly 19 disseminated.”). However, the simple fact that Arena had an explanation for its view of the data does not mean investors would 20 not want to know that Arena and the FDA were at odds. Arena could have remained silent about the dispute or it could have 21 addressed its discussions with the FDA head-on. But it could not represent that there was no controversy here because all the data was 22 favorable. 23 Arena, 840 F.3d at 709 (9th Cir. 2016). Here, the allegations of manipulation are closer to the 24 false misrepresentations in Arena than to the reasonable belief of FDA approval in AstraZeneca. 25 Unlike AstraZeneca, the allegations do not simply amount to honest and “favorable [analysis] . . . 26 on the risk-benefit issue . . . backed up by a large body of details from AstraZeneca's research.” 27 AstraZeneca, 559 F. Supp. 2d at 471. Here, Defendants allegedly manipulated data in order to 1 Second, Endologix is not dispositive; the argument that FibroGen had no reason to invest 2 in a drug that they knew would not receive FDA approval fails because Plaintiffs do not argue that 3 Defendants believed that the FDA would deny approval. Plaintiffs allege that Defendants 4 withheld the true data from both the market and the FDA by manipulating the nine Phase 3 safety 5 analyses. See CAC ¶ 84. Plaintiffs’ theory is that Defendants believed they would have obtained 6 FDA approval through manipulation. This manipulation brings this case closer to Arena, where 7 the defendant expressed confidence in FDA approval while defendants concealed safety and 8 efficacy issues. The allegations here differ from the honest disagreement over the clinical data in 9 Astrazeneca. 10 Furthermore, an instance of scienter is supported by In re Rigel, which specifically 11 discussed post-hoc changes to data:

12 [A] post-hoc adoption of a statistical method could raise concerns regarding reliability, biased scientific methods, or even 13 fraud. See United States v. Harkonen, No. C 08–00164, 2010 WL 2985257, at *4, 7–10 (N.D. Cal. July 27, 2010). Because there are 14 many ways to statistically analyze data, it is necessary to choose the statistical methodology before seeing the data that is 15 collected during the clinical trial; otherwise someone can manipulate the unblinded data to obtain a favorable result. Id. 16 at *4. Thus, the principal features of the statistical analysis usually are included in the protocol and the statistical analysis plan is 17 finalized before the data is unblinded. 18 In re Rigel, 697 F.3d at 879. Defendants do not dispute post-hoc changes were made. See, e.g., 19 CAC ¶¶ 7, 71, 110, 152, 159, 175, 182, 245 (“‘post[-]hoc changes’ were made to every single one 20 of nine clinical trial analyses after the data had been fully unblinded[,]” amounting to data- 21 dredging). The dubiousness of post-hoc changes supports an inference of scienter. 22 b. Confidential Witnesses 23 Scienter is supported in this case by confidential witnesses. The CAC includes allegations 24 by confidential witnesses in senior positions at AstraZeneca (“CW”). CAC ¶ 120. The CAC 25 alleges that these employees uniformly confirmed that post-hoc changes to the data were made by 26 FibroGen’s most senior officers. Id. ¶¶ 121, 129, 130. According to the witnesses, AstraZeneca 27 and FibroGen became aware that the FDA had identified issues regarding Roxadustat’s safety data 1 several months before Defendants were forced to reveal the truth and were telling investors the 2 exact opposite. CAC ¶¶121, 129, 130; Opp’n at 31 (citing CAC ¶¶ 250–51). 3 The CW testimony here is probative.

4 [W]here a complaint relies on statements from confidential witnesses, it must “pass two hurdles to satisfy the PSLRA pleading 5 requirements. First, the confidential witnesses whose statements are introduced to establish scienter must be described with sufficient 6 particularity to establish their reliability and personal knowledge. Second, those statements which are reported by confidential 7 witnesses with sufficient reliability and personal knowledge must themselves be indicative of scienter. 8 9 Iron Workers Loc. 580 Joint Funds v. NVIDIA Corp., 522 F. Supp. 3d 660, 674 (N.D. Cal. 2021) 10 (citing Zucco Partners, 552 F.3d at 995 (internal citations and quotation marks omitted)). 11 Plaintiffs have met the first prong. “The Ninth Circuit has held that numbering the 12 confidential witnesses and describing the witnesses’ job description and responsibilities 13 constitutes a ‘large degree of specificity,’ especially where the witnesses’ exact title is used.” 14 Mulligan, 36 F. Supp. 3d at 961 (quoting Daou, 411 F.3d at 1016). Here, each of the confidential 15 witnesses is numbered with their specific job titles. CAC ¶¶ 121–23. CW1 was a former Senior 16 Director of Global Marketing Roxadustat-Global Product Portfolio Strategy Cardio Renal at 17 AstraZeneca from February 2014 until May 2021 and a senior member of the global launch of 18 Roxadustat in China and the United States. Id. Regarding Roxadustat, CW 1 was responsible for 19 leading the cross-functional team in the development of the drug’s Global commercial strategy. 20 Id. CW 2 is a former AstraZeneca Renal Sales Specialist who was part of the team preparing to 21 commercialize Roxadustat from January 2019 until January 2021, and CW 3 is a former 22 AstraZeneca Global Vice President of Renal and Anemia Therapeutic Areas from November 2013 23 until January 2021. Id. CW 3 was responsible for expanding the global anemia team delivering 24 the first launch of Roxadustat. Id. These details regarding the confidential witnesses are sufficient 25 to satisfy the first prong. Kong v. Fluidigm Corp., No. 20-CV-06617-PJH, 2021 WL 3409258, at 26 *10 (N.D. Cal. Aug. 4, 2021) (finding that the first prong was satisfied when the FAC provided 27 titles and tenures for each CW, as well as job descriptions); accord Impax, 36 F. Supp. 3d at 963. 1 were not involved in Roxadustat’s clinical trials, analysis of clinical data, submission of the NDA, 2 or communications with the FDA. Defs. Mot. at 27. However, a confidential witness need not be 3 involved in the NDA process itself to have personal knowledge regarding the allegations. The 4 CWs allege that FibroGen shared information about the clinical data with AstraZeneca’s 5 commercial team. CAC ¶ 124. Although the data shared was allegedly limited and provided 6 mainly FibroGen’s side of the story, this was one of the reasons for their suspicion, as full clinical 7 trial data was normally readily available to them. Id. ¶¶ 121, 124–25. In addition, the CW’s role 8 as the Roxadustat sales and launch team reasonably explains their insight regarding the ongoing 9 NDA process, which is the most critical issue in the global launch of Roxadustat. Id. ¶ 129 10 (“[T]hey backed off completely on the training, which told us that something was going on with 11 the FDA approval.”). 12 Defendants also argue that the CAC does not allege that any of the CWs had direct 13 interaction with any Defendant; thus, the CW allegations do not establish personal knowledge of 14 the defendants’ mental state. While CW1 and CW2 are not alleged to have had any direct 15 interactions with Defendants, CW3 had attended boardroom meetings during which Dr. Yu 16 presented data. CAC ¶ 125. CW3 alleges that these data reflected the altered post-hoc analyses 17 and that the accurate, prespecified analyses were withheld from AstraZeneca. Id. Regarding the 18 black box warning, CW3 alleges with personal knowledge that “[w]e sat down with the 19 [FibroGen] team and got an update on where things were and the direction where they were 20 heading, and we were told that we are likely going to end up with a [Black Box] warning in the 21 fall of 2020.” CAC ¶ 130 (quotation marks omitted). Therefore, CW3 had personal knowledge 22 from direct interaction with Dr. Yu and the FibroGen team. Furthermore, CW1 has personal 23 knowledge as to AstraZeneca’s role in launching Roxadustat and difficulties with coordinating its 24 efforts with FibroGen. See CAC ¶ 121. 25 For the foregoing reasons, the CW allegations together raise an inference of scienter. 26 c. Newspaper Articles and Analyst Reports 27 Scienter is also supported by the reaction of the scientific and financial community to the 1 community universally concluded that Defendants’ manipulations were intentional and called it 2 the “worst case of data manipulation in years” that “could [not have] happen[ed] accidentally.” 3 Opp’n at 30; CAC ¶ 3. 4 Defendants dispute these reactions as pure speculation and conjecture. Defs. Mot. at 27 5 (quoting In re Wet Seal, Inc. Sec. Litig., 518 F. Supp. 2d 1148, 1172–73 (C.D. Cal. 2007) 6 (“[c]onclusory allegations of wrongdoing are no more sufficient if they come from a newspaper 7 article than from plaintiff's counsel”); Campo v. Sears Holding Corp., 371 F. App’x 212, 215 (2d 8 Cir. 2010) (“press speculation about defendants’ motives” are not “specific, well-pleaded facts”)). 9 Defendants are correct that the alleged contents of the articles are conclusory. In re Wet 10 Seal, 518 F. Supp. 2d at 1172 (“[N]ewspaper articles should be credited only to the extent that 11 other factual allegations would be—if they are sufficiently particular and detailed to indicate their 12 reliability. Conclusory allegations of wrongdoing are no more sufficient if they come from a 13 newspaper article than from plaintiff's counsel . . .” (citations omitted)). However, while these 14 articles and reports do not establish scienter by themselves, they lend some support to the extent 15 that analysts and experts, including a nephrologist who was involved in the Roxadustat clinical 16 trials, were quoted for their opinions. For example, Dr. Daniel Coyne is alleged to be a professor 17 and a nephrologist who worked as a site investigator in the Roxadustat clinical trials and is quoted 18 in an article: “This deeply damages the reputation of FibroGen . . . I feel very misled, and I don’t 19 think there is any excuse for this. I don’t know how this could happen accidentally.” Opp’n at 20 30, n.21 (emphasis in original) (quoting CAC ¶¶10, 96)). 21 d. Approval Around the World 22 According to Defendants, the fact that Roxadustat received regulatory approval in the 23 second to eighth biggest pharmaceutical markets in the world between 2018 and 2021 shows a 24 lack of scienter. See Defs. Mot. at 23; Defs. Reply at 6. This is a helpful fact for Defendants but 25 does not undermine the plausibility of Plaintiff’s allegations. Different countries have different 26 requirements and criteria for the approval of a drug; therefore, approvals in other countries do not 27 guarantee approval in the United States. Cf. Endologix, 962 F.3d at 419 (affirming dismissal and 1 the progress of the U.S. clinical trial, despite the unfavorable reports from Europe). As such, 2 Roxadustat’s favorable stance in other countries, while relevant, does not in itself negate 3 Defendants’ scienter regarding Roxadustat’s potential in the U.S. 4 e. The April 6, 2021 Admission 5 Plaintiffs contend the April 6, 2021 press release was an admission of manipulation of the 6 data. Defendants dispute that characterization. According to Defendants, the fact that a new CEO 7 (Conterno) and a new CMO (Eisner) concluded that additional disclosures should be made shows 8 transparency and cuts against scienter. Defs. Reply 7; Defs. Mot. at 23. 9 Plaintiffs plausibly respond that the press release does not indicate transparency; 10 Defendants were forced to release their admission in April 2021 because the FDA called for an 11 AdCom the month prior. Opp’n at 31. And Plaintiffs allege that even at this point, Defendants 12 failed to disclose the results of crucial FDA prespecified sensitivity analyses showing that 13 Roxadustat was less safe than placebo and Epogen in all studied populations. Id.; CAC ¶ 249. 14 According to Plaintiffs, it was the FDA that later revealed the full truth about the negative safety 15 profile for Roxadustat, and Defendants’ concealment, in fact, indicates that they understood their 16 likely effect on the market and scienter. Opp’n at 31. 17 Therefore, Plaintiffs have sufficiently alleged scienter because: (1) the press release 18 admitted that Defendants made “post-hoc changes to the stratification factors,” and (2) Defendants 19 allegedly falsely touted this manipulated data for over two years. Opp’n at 29–30 (citing Immune 20 Response, 375 F. Supp. 2d at 1022 (“[T]he fact that the defendants published statements [about 21 clinical trial results] when they knew facts suggesting the statements were inaccurate or 22 misleadingly incomplete is classic evidence of scienter.”); BioMarin, 2022 WL 164299, at *14 23 (finding scienter when “the defendants allegedly told the market things that were allegedly not true 24 and that [they] must have known were not true by their nature”); In re MannKind, 835 F. Supp. 2d 25 at 815 (finding scienter “based on the falsity of the statements and Defendants’ access to 26 information contradicting those statements,” particularly where “the company’s interactions with 27 the FDA” were “absolutely integral to [its] success”)). 1 specific responses to questions that falsely implied that the data was sanctioned by the FDA. 2 Opp’n at 31 (citing ¶¶ 247–48; In re Qualcomm Inc. Sec. Litig., 2019 WL 1239301, at *11 (S.D. 3 Cal. Mar. 18, 2019) (“specific [statements] … in response to questions from analysts and 4 investors” contributed to a strong scienter inference)). An excerpt from FibroGen’s November 11, 5 2019 earnings call following the ASN conference reads in part:

6 Q: I would just like to understand, since there seems to be some investor concern about FDA agreements and FDA sign-off [ from ] 7 statistical [ stance/plans ]14, how your general impression was of your meeting with the FDA? And why you feel confident about 8 statistical protocols and their signing off of what you have from statistics and why you feel good about that? 9 A: First of all, I wanted to share that we have been in dialogue with 10 the FDA in the past 6 years. And there has been a very good understanding about what the Phase III required study would look 11 like and including the size of the study, how to power it [ for example ] what's the primary endpoint and we agree on time to meet 12 at the primary endpoint, and that's how we power for the non- dialysis and the dialysis. And we've also had a very productive 13 dialogue with the FDA on the analysis of cardiovascular safety as well as what the efficacy requirement needs to be for this 14 submission. And the most recent conversation with the FDA was at the end of July. And we had sent it to the FDA, a fairly 15 comprehensive briefing package and had a very productive meeting. And walking out of it, we felt that we had all the guidance from the 16 FDA we needed to put together a winning submission.

17 Q: So you feel no issue or no real concern about the hazard ratios and the [ upper bounds ] and all the things that people are 18 talking about? You look at diabetes programs and things like that, there's -- you're well within that. So you don't feel any concern 19 about that?

20 Yu: No, we have no concern about that. And Mike, as you know, that our regulatory assessment is not based on 1 criterion. But 21 instead, it is based on totality of evidence such as efficacy, safety, what is the medical need. And so based on our discussions and the 22 historical precedents in this therapeutic area and the various conversations we've had with the agency, we are very comfortable 23 with our data where it is now.

24 . . .

25 Q: My second question is when are you going to talk about the [ the job ] as stat plan? I mean the statistical analysis plan, including the 26 non-inferiority margin. Is there any pre-planned FDA meeting in the coming weeks? 27 . . . 1 Schoeneck: I think is -- the question is when will we talk to the 2 FDA about the statistics and the analytical plan is the question. . . . 3 Yu: Okay. So the answer to that question is that we had already 4 talked with the FDA about analytical plan, and we had made the agreement on the analysis plan. The results that we have 5 presented in the high-impact clinical session at the ASN, and the numbers I had just presented were based on the agreed analysis 6 plan that we have made with the FDA.

7 Q: So the noninferiority margin of [ 1.3 ] is already in agreement or not? 8 Yu: So we are talking about the analysis plan, meaning how do you 9 pool, what's the pooling strategy and the analysis plan, how to analyze the data. When you talk about NI margins, you're talking 10 about the standard for assessment, right? And as I mentioned earlier, that we expect that [ all ] regulators will assess the data 11 based on the very -- all the -- on the entire application of the NDA. And based on our dialogue with FDA over the past 6 years and the 12 data, as we have shown, we are confident that we do have what it takes for this drug to be favorably evaluated. 13 14 Docket No. 111 at 137–40. A few days later, FibroGen emailed a short seller that questioned 15 whether Roxadustat’s data reflected FDA-required analyses that: “The data presented at [ASN] 16 reflect the analytical methods and study pools agreed upon with the FDA.” CAC ¶ 179. Such 17 specific answers to specific questions regarding the non-inferiority margin and analysis plans 18 suggest that Defendants knew their importance yet consciously attempted to give a favorable 19 impression while hiding their manipulation and unfavorable analyses.15 These specific allegations 20 are sufficient to plausibly allege scienter. 21 f. Yu’s Resignation16 22 Plaintiffs further cite Yu’s resignation as further evidence of scienter. According to 23 15 Defendants also point out that the additional analyses in the press release had already been 24 shared with the FDA, did not result in the withdrawal of the analyses disclosed in 2019 or indicate any issue with the integrity of the underlying data. Defs. Mot. at 23. However, the belated 25 sharing of additional data with the FDA does not make the allegedly manipulated data any less false. Furthermore, it is not the integrity of the underlying data that is disputed, but their analysis. 26

16 Yu also asks to dismiss claims to the extent any allegations are about acts or omissions 27 occurring after Yu resigned and left FibroGen because she is no longer a “control person” under 1 Plaintiffs, Yu abruptly announced her resignation on November 27, 2020, on the cusp of gaining 2 regulatory approval for its flagship drug after years of development. CAC ¶ 72. Just three weeks 3 after the unexpected retirement, FibroGen announced that the FDA had extended the review 4 period of the NDA for Roxadustat by three months. Id. ¶ 73. Therefore, Plaintiffs allege that 5 FibroGen “pushed out its Chief Medical Officer who was directly responsible for this very data, 6 under highly suspicious circumstances.” Id. ¶ 72. 7 Yu argues that her resignation is not suspicious nor indicative of scienter. Yu Mot. at 14– 8 15; Yu Reply at 13. Yu points out that she left with praise from the new CEO and that an internal 9 investigation exculpated her of any inference of bad faith or wrongdoing, according to a Form 10- 10 Q submission to the SEC. Yu Mot. at 14–15 (the new CEO praised her for her expertise and 11 leadership on Roxadustat); Yu Reply at 13. However, the CEO’s general praise of her work does 12 not exculpate her involvement in the alleged manipulation of data. Furthermore, the submission to 13 the SEC merely states that “[t]hose responsible for the statistical analyses believed that it was a 14 reasonable and valid way to analyze and present the data.” Docket No. 111, Ex. YY at 86. This 15 rather conclusory and self-serving submission is hardly an exculpation of her involvement. 16 While Yu is correct that a resignation by itself is an insufficient indication of scienter, her 17 abrupt resignation tends to support scienter and may be considered together with other allegations, 18 including statements by confidential witnesses and the compensation she received, because 19 scienter is reviewed holistically. Reese v. Malone, 747 F.3d 557, 569 (9th Cir. 2014) (citing 20 Tellabs, 551 U.S. at 323 (“The relevant inquiry is whether all of the facts alleged, taken 21 collectively, give rise to a strong inference of scienter, not whether any individual allegation, 22 scrutinized in isolation, meets that standard.” (quotation marks and citation omitted)). 23 g. Insider Trading 24 Insider trading can establish scienter. However, the Ninth Circuit has long made clear that 25 “routine business objectives, without more, cannot normally be alleged to be motivations for 26 fraud” as “to hold otherwise would be to support a finding of fraudulent intent for all companies.” 27 Lipton v. Pathogenesis, 284 F.3d 1027, 1038 (9th Cir. 2002). Only “unusual” or “suspicious” 1 times calculated to maximize personal benefit may support a strong inference of scienter in the 2 Ninth Circuit. See In re Quality Sys., 865 F.3d at 1146; Metzler, 540 F.3d at 1066–67. “Three 3 factors are relevant to this inquiry: (1) the amount and percentage of the shares sold; (2) the timing 4 of the sales; and (3) whether the sales were consistent with the insider's trading history.” Metzler, 5 540 F.3d at 1067. Furthermore, “a lack of stock sales can detract from a scienter finding.” Webb 6 v. SolarCity Corp., 884 F.3d 844, 856 (9th Cir. 2018). 7 Plaintiffs allege that Individual Defendants engaged in insider trading totaling over $42 8 million and over 80% of the total insider sales for the entire Company during the Class Period. 9 CAC ¶ 135. Defendants dispute CAC’s allegations of insider trading. According to Defendants, 10 Cotroneo and Schoeneck both sold substantially more shares in the 31-month period before the 11 Class Period than during it. Defs. Mot. at 25; Defs. Reply at 7. Yu, who was not employed by 12 FibroGen the entire time, and Neff, who passed away during the Class Period, also sold more 13 shares pre-Class Period compared to the time they were at FibroGen.17 See Defs. Mot. at 24–26. 14 Defendants are correct that these stock sales are not out of the ordinary and fail to raise a strong 15 inference of scienter. 16 i. Cotroneo, Yu and Schoeneck 17 Yu’s, Cotroneo’s, and Schoeneck’s pre-class period sales are larger than class period sales. 18 Plaintiffs focus on specific instances, including Cotroneo’s largest sale on December 20, 2019, 19 which was allegedly well-timed to take advantage of a 22% increase in the stock price following 20 FibroGen’s release of false safety data on November 8, 2019. However, this single sale is 21 insufficient to show that Defendants’ trading practice fell “dramatically out of line with prior 22 trading practices at times calculated to maximize the personal benefit from undisclosed inside 23 information.” Silicon Graphics, 183 F.3d at 986 (quotation marks and citations omitted). 24 Plaintiffs argue that this largest sale of 59,456 shares was a deviation compared to his prior sales 25 of 3,201 shares each on June 18, 2019 and September 17, 2019. However, these figures are taken 26 out of context; Cotroneo had made even larger sales pre-Class Period. See Docket No. 110 27 1 (Kasner Decl.), App’x B. For example, Cotroneo sold 95,000 shares on August 10, 2017. See id. 2 In the year the Class Period started, he had also sold 49,500 on February 16, 2018. See id. 3 Although Plaintiffs seem to emphasize the temporal proximity of the sale, a three-week wait 4 between the false statements and the stock sale is not strong compared to Plaintiffs’ cited case 5 involving sales just a week after the release of positive information. Opp’n at 32 (citing Azar v. 6 Yelp, Inc., No. 18-CV-00400-EMC, 2018 WL 6182756, at *19 (N.D. Cal. Nov. 27, 2018) 7 (“temporal proximity between the sales and the release of” positive information “could support an 8 inference of scienter”)). Plaintiffs do not provide specific deviations in trade history for Yu and 9 Schoeneck. As such, Yu’s, Cotroneo’s, and Schoeneck’s trade histories do not plausibly establish 10 scienter. 11 ii. Neff 12 Neff was alive only during the first eight months of the Class Period. Plaintiffs point out 13 that Neff sold over fifty thousand more shares during the Class Period than the eight months 14 before. Opp’n at 32. However, his sales were not “dramatically out of line with prior trading 15 practices” because he sold the exact same number of 237,816 shares in 3-month intervals18, both 16 eight months prior to the Class Period and during the Class Period. Defs. Reply at 7. Although 17 Plaintiffs argue that Neff unloaded 317,000 shares in the three months after the May 2019 press 18 release, Opp. at 32, Neff sold a similar number of sales of 306,360 shares in the same period 19 before then. Kasner Decl., App’x D. As such, while calculations using different time intervals 20 account for some differences, Neff did not engage in stock trading that was dramatically out of 21 line with prior trading practices. 22 iii. Conterno and Eisner 23 Conterno and Eisner joined FibroGen during the Class Period. According to Defendants, 24 the fact that they did not sell any shares during the Class Period and that Conterno actually 25 purchased shares cuts against scienter. Defs. Mot. at 25–26 (citing Kasner Decl. ¶ 70; In re 26 Leapfrog Enter., Inc. Sec. Litig., 237 F. Supp. 3d 943, 952 (N.D. Cal. 2017) (explaining that 27 1 purchase of stock “strongly weighing against scienter”)). 2 The Court finds that these facts do not support either side in determining scienter. 3 Conterno was required to buy and maintain ownership of shares valued at five times his base 4 salary when he joined FibroGen. Opp’n at 32, n.25. Eisner was also required to meet minimum 5 stock ownership amounts, and Defendants fail to provide any contrary explanation in the reply. 6 Because there is a reasonable explanation for the purchases and lack of sales of stock, there is no 7 inference of scienter favoring either side. Id. 8 iv. 10b5-1 Plans 9 Plaintiffs’ attempt to establish Defendants’ scienter through their stock sales fails for an 10 additional reason. “[T]he weight of authority in the Ninth Circuit” holds that courts can consider 11 10b5-1 trading plans when evaluating allegations concerning scienter.” Yelp, 2018 WL 6182756, 12 at *4. “In general, automatic sales made pursuant to Rule 10b5-1 plans do not support a strong 13 inference of scienter.” Rodriguez, 325 F. Supp. 3d at 1056. 14 According to Defendants, each and every stock sale alleged during the Class Period was 15 made pursuant to 10b5-1 plans. Defs. Mot. at 26. Plaintiffs respond that the fact that the sales 16 were made pursuant to Rule 10b5-1 plans does not preclude a finding of fraud if, at the time the 17 plans were adopted, the individual defendants were allegedly already aware of the falsity of their 18 statements. Opp’n at 33, n.26 (citing Applestein v. Medivation, Inc., No. C-10-0998 EMC, 2011 19 WL 3651149, at *7 (N.D. Cal. Aug. 18, 2011). Plaintiffs also point out that in Yelp, this Court 20 found that it cannot conclude that the 10b5-1 plan negated any inference of scienter without 21 reviewing the defendant’s actual trading plan. Yelp, 2018 WL 6182756, at *19. This Court 22 reasoned:

23 To be sure, stock sales made “according to pre-determined plans may rebut an inference of scienter.” Metzler Inv. GMBH v. 24 Corinthian Colleges, Inc., 540 F.3d 1049, 1067 n.11 (9th Cir. 2008) (emphasis added). But all that can be gleaned from the Forms 4 is 25 that Stoppelman's “[s]hares were sold pursuant to a duly adopted 10b5-1 trading plan.” . . . Defendants assert that the trading plan 26 was “executed prior to the alleged fraud,” Mot. at 19, but nothing before the Court establishes when precisely the trading plan was 27 adopted. Defendants have not sought to introduce the actual only if the insider adopted the plan “[b]efore becoming aware of the 1 [material nonpublic] information.” 17 C.F.R. § 240.10b5-1(c)(1)(i); see Applestein v. Medivation, Inc., No. C-10-0998 EMC, 2011 WL 2 3651149, at *7 (N.D. Cal. Aug. 18, 2011) (concluding that the “fact that the sales were made pursuant to Rule 10b5–1 plans does not 3 preclude a finding of fraud because, at the time the plans were adopted ... the individual defendants were allegedly already aware of 4 the unblinding”). 5 Id. at *18. 6 Defendants submit SEC Form 4 for each Defendant, and each transaction during the Class 7 Period includes a footnote that “Shares [were] sold pursuant to a 10b5-1 plan.” See Docket No. 8 111, Ex. AAA. Therefore, although it is not entirely clear when precisely the trading plan was 9 adopted, they were at least adopted prior to the Class Period. Furthermore, Plaintiffs have not 10 alleged that Defendants were already aware of the falsity of their statements at the time their plans 11 were adopted. Plaintiffs’ citation to BioMarin is also inapposite. Plaintiffs argue that “even if the 12 trades were pre-planned, ‘concealing [] negative information before the sale and setting the sale to 13 occur prior to the PDUFA [(final review of the NDA submission by the FDA)] date were 14 discretionary choices, so it is sufficient at the pleadings stage to contribute to the plausibility of the 15 scienter allegations.’” Opp’n at 33 n.26 (quoting BioMarin, 2022 WL 164299, at *14). However, 16 BioMarin involved defendants who had sold a much greater number of shares during the class 17 period in comparison to the period prior to it and argued that the non-discretionary nature of the 18 sales “lessen[ed] the implication that they were improper.” 2022 WL 164299, at *14. This case is 19 distinguishable by the fact that the pre-Class Period sales surpass the Class Period sales. Because 20 the stock sales were made pursuant to 10b5-1 plans, they “do not support a strong inference of 21 scienter.” Rodriguez, 325 F. Supp. 3d at 1056. Plaintiff’s attempts to argue that there is a strong 22 showing of scienter despite their existence also fails. 23 h. Compensation 24 The Ninth Circuit has previously found that “[a] strong correlation between financial 25 results and stock options or cash bonuses for individual defendants may occasionally be 26 compelling enough to support an inference of scienter.” Zucco Partners, 552 F.3d at 1004. This 27 inference of scienter depends on the particularity of the compensation allegations: defendants' compensation was based “principally” on the 1 defendant company's financial performance. 320 F.3d at 944. The complaint at issue in America West established this fact by 2 comparison of the individual defendants' prior year's compensation with the year in question, noting that while “none 3 of the executive officers received option awards in 1997 for the previous year,” in the year in question “America West awarded 4 Franke 350,000 options ... [and] awarded 110,000 options to Goodmanson, 35,000 options to Parker, and 20,000 options to Garel 5 in March 1998.” 6 Id. at 1004–05. However, courts have distinguished general allegations that bonuses were related 7 to a company’s financial performance:

8 general allegations that “executive-level bonuses were ‘based in part’ on [a company's] financial performance ... are inadequate to 9 meet the heightened pleading requirements of Silicon Graphics and Tellabs.” Zucco Partners, LLC v. Digimarc Corp., 552 F.3d 981, 10 1005 (9th Cir.2009). For bonuses to support an inference of scienter, the allegations in the complaint must demonstrate a 11 strong correlation—including comparisons to previous years' bonuses—between the bonuses and the company's “bottom 12 line”. Id. 13 In re Downey Sec. Litig., No. CV 08-3261-JFW(RZX), 2009 WL 2767670, at *13 (C.D. Cal. Aug. 14 21, 2009). 15 The CAC alleges that the individual defendants and FibroGen had compensations tied to 16 regulatory and commercial milestones. CAC ¶ 44, 66. Plaintiffs do not provide a comparison of 17 compensations to previous years for Conterno and Eisner (both joined FibroGen during the Class 18 Period) and Neff (died in 2019).19 Plaintiffs also do not provide a comparison to the previous 19 year’s compensation for Yu and Cotroneo but provide compensations for 2019 and 2020 during 20 the Class Period. However, the compensations in 2019 are significantly higher compared to 2020, 21 which are explicitly attributed to the submission of the Roxadustat NDA in December 2019: 22 1. Yu 23 • 2019: $5,856,451, including $3,044,223 in stock awards, $1,886,018 in option 24 awards, $590,000 in salary, $316,830 in non-equity incentive plan compensation, 25 and $19,380 in other compensation. CAC ¶¶ 24, 138. 26 • 2020: $3,512,764, including $1,201,950 in option awards, $1,188,450 in stock 27 1 awards, $612,000 in salary, $459,000 in non-equity incentive plan compensation, 2 and $51,364 in other compensation. Id. 3 2. Cotroneo 4 • 2019: $4,326,386, including $1,769,851 in option awards, $1,782,963 in stock 5 awards, $490,000 in salary, $264,600 in nonequity incentive plan compensation, 6 and $18,972 in other compensation. Id. ¶¶ 28, 138. 7 • 2020: $2,916,018, including $1,061,723 in option awards, $1,056,400 in stock 8 awards, $508,000 in salary, $230,937 in non-equity incentive plan compensation, 9 and $58,959 in other compensation. Id. 10 Plaintiffs also allege that Yu’s high compensation in 2019 was directly tied to Roxadustat, 11 as FibroGen’s Proxy states that the compensation was “for her efforts in the completion of the 12 [R]oxadustat pooled MACE safety data analyses” and “the [R]oxadustat [NDA] submission to the 13 [FDA].” CAC ¶ 138. Yu received over $10 million in stock and option awards tied to these 14 achievements, which accounted for the lion’s share of Yu’s Class Period compensation (79% in 15 2018; 84% in 2019; and 68% in 2020). Id. It can be reasonably inferred that without the data 16 manipulation that concealed significant health risks that resulted in a unanimous decision against 17 the drug’s approval, the NDA submission would have been unlikely. 18 While there is no comparison of compensation to the years prior to the Class Period, the 19 figures alleged by Plaintiffs lend some support to Plaintiffs’ allegations of scienter. For example, 20 a court found that there was a sufficiently strong correlation between the defendants’ financial 21 performance and their stock and cash awards to support a finding of scienter when the CAC 22 alleged specific stock and cash award multipliers tying their compensation to financial 23 performance and provided tables alleging precise amounts each executive received in base salary, 24 stock award, and cash awards showing that the defendants’ stock and cash awards far outstripped 25 their base salaries. See Evanston Police Pension Fund v. McKesson Corp., 411 F. Supp. 3d 580, 26 603 (N.D. Cal. 2019). Here, Plaintiffs have alleged that FibroGen’s Proxy expressly ties some 27 individual defendants’ large compensation to the NDA submission relying on manipulated data. 1 salaries were merely a tenth of their other forms of compensation, most of which was stock and 2 option awards.20 CAC ¶¶ 24, 28, 138. Accordingly, Defendants’ compensation structure suggests 3 some degree of scienter. 4 i. Group Pleading 5 Defendants argue that Plaintiffs are required to plead scienter separately for each 6 defendant, yet Plaintiffs group them all together to find scienter. Defs. Mot. at 26 (citing Cheung 7 v. Keyuan Petrochemicals, Inc., 2012 WL 5834894, at *4 (C.D. Cal. Nov. 1, 2012)). According to 8 Defendants, the CAC “does not make sense” because it attributes statements and admissions to 9 Defendants generally when the statements themselves were made by individuals. Id. For 10 example, the April 6, 2021 press release is discussed as Defendants’ collective admission when 11 only Conterno made the alleged statements in that press release, and Yu had already retired from 12 FibroGen by this time. Id. Similarly, the CAC also refers generally to “Defendants’ … 13 confirm[ation of] their personal participation in the pre-NDA meeting with the FDA” in July 2019, 14 when Conterno and Eisner had not yet joined FibroGen. Id. However, while it is true that the 15 CAC does often group the defendants together in its allegations, the CAC does attribute each 16 statement to a specific Defendant in the chart summarizing each allegedly false and misleading 17 statement. See generally Docket No. 91-2. 18 Plaintiffs have sufficiently alleged scienter, at least for some individual defendants. For 19 example, Yu was the Chief Medical Officer who was “directly responsible for this very 20 [manipulated] data[.]” CAC ¶ 72. Yu retired abruptly on November 27, 2020, three weeks before 21 FibroGen announced that the FDA had extended review of the NDA. Id. ¶¶ 72–73. CW3 alleges 22 that Defendant Yu presented data at the meeting that appeared incomplete. Id. ¶ 124. CW 3 23 believed that the data shown at meetings, which was later revealed as the altered post-hoc 24 analyses, had been agreed to by the FDA at the time. Id. ¶ 125. Yu also received over $10 million 25 in restricted stock and option awards that were based in large part on her efforts “in the completion 26 20 Yu argues that these awards were tied to the completion of the safety studies and submission to 27 the NDA, as opposed to their results. Reply at 13. However, this argument is unconvincing. If 1 of the Roxadustat MACE safety analysis” and the submission of the Roxadustat NDA to the FDA. 2 Id. ¶ 138. 3 Specific facts alleged regarding Conterno also show an inference of scienter. On February 4 25, 2020, Conterno stated that he had personally reviewed the Roxadustat MACE safety data and 5 that based on his extensive experience “conduct[ing] and be[ing] a part of a number of 6 cardiovascular studies in my previous roles,” the Roxadustat safety data was “extremely clean” 7 and “highly compelling” because they had definitively shown “safety against what I think is a very 8 high hurdle of placebo” in every single MACE category. Id. ¶¶ 67, 184. Statements touting 9 manipulated analyses, despite Conterno’s expertise and personal review of the data, create an 10 inference of scienter. 11 Specific allegations as to other Defendants are weaker. Schoeneck and Cotroneo oversaw 12 the submission of the Roxadustat NDA application and reviewed, approved, signed, and certified 13 FibroGen’s filing with the SEC. Id. ¶ 20, 22. Cotroneo received large compensations in 2020 14 related to Roxadustat. Id. ¶¶ 28, 138. Eisner discussed post-hoc changes at the April 6, 2021 15 press conference, which Plaintiffs allege was false because Defendants withheld analyses showing 16 that the drug was materially inferior. Id. ¶ 103; Statements Chart, Statements # 83–89. Plaintiff’s 17 specific allegations against Schoeneck, Cotroneo, and Eisner, by themselves, are insufficient to 18 create a strong inference of scienter. 19 j. Core Operations Theory 20 Finally, Plaintiffs rely on the core operations theory of scienter. The core operations 21 inference allows a court to impute inference of scienter to individual defendants when “the nature 22 of the relevant fact is of such prominence that it would be absurd to suggest that management was 23 without knowledge of the matter.” Prodanova v. H.C. Wainwright & Co., LLC, 993 F.3d 1097, 24 1111 (9th Cir. 2021).

25 There are three circumstances under which core operations allegations can support a strong inference of scienter: (1) when 26 they, along with other allegations, support a cogent and compelling inference of scienter, (2) when they are themselves particular and 27 suggest that the defendants had actual access to the disputed prominence that it would be absurd to suggest that management was 1 without knowledge of the matter.” 2 Id. 3 For example, the In re MannKind plaintiffs similarly alleged that the defendants 4 misrepresented to investors facts relating to the existence and likelihood of FDA approval by 5 stating that a study they were performing had been “blessed” and “vetted” by the FDA even 6 though it had not, that it was designed based on FDA recommendations even though it was not, 7 and that the FDA accepted all of the bioequivalence studies even though it had not. In re 8 MannKind, 835 F. Supp. 2d at 803. The court found that the plaintiff raised an inference of 9 scienter “based on the falsity of the statements and Defendants' access to information contradicting 10 those statements. Moreover, the company's interactions with the FDA regarding [the drug’s] 11 approval were absolutely integral to the company's success, and it would therefore be absurd to 12 suggest that management was without knowledge of the matter.” Id. at 815 (internal quotation 13 marks and citations omitted). 14 Defendants argue that the court cannot simply apply this inference just because the alleged 15 fraud is related to “FibroGen’s single most important drug” because doing so would “turn it into 16 an automatic presumption of comprehensive knowledge on the part of management.” Defs. Mot. 17 at 27, n. 18 (quoting Browning v. Amyris, Inc., 2014 WL 1285175, at *15 (N.D. Cal. Mar. 24, 18 2014)). However, the Browning court further explained that “[t]o avail themselves of this prong, 19 the plaintiffs must justify their invocation based on more than a mere assertion that all CEOs 20 should want their companies to succeed and therefore ought to know everything about their 21 business.” Id. The court also explicitly distinguished its case from In re MannKind:

22 In re MannKind Securities Actions involved discrete events that had critical importance to the businesses at issue: stop-orders for a small 23 number of contracts that affect a huge portion of a company's revenue and regulatory approval of a company's most important 24 drug. It makes sense that the companies' management would or should know the relevant facts about those issues. The courts 25 reasonably expected management to be apprised of those matters. Here, the plaintiffs appear to charge Melo with knowing whether 26 Amyris would successfully meet its projections or not. 27 Id. Like In re MannKind, the approval of Roxadustat goes beyond a mere assertion that 1 Furthermore, Roxadustat’s viability was critical to FibroGen: “[A]nalysts estimated that 2 between 85-90% of FibroGen’s $3.7 billion market value ‘stem[med] primarily from [the 3 financial prospects of FibroGen’s] flagship drug Roxadustat.’” CAC ¶ 42 (emphasis in 4 original). FibroGen is alleged to have stated that its “revenue to date” was “generated primarily 5 from [its] collaboration agreements . . . for the development and commercialization of 6 Roxadustat,” with “substantially all” of its revenue being generated in this manner for the years 7 covering the Class Period. Id. ¶ 43. FDA’s approval and FibroGen’s interaction with the FDA 8 were arguably “absolutely integral to the company’s success.” In re MannKind, 835 F.Supp.2d at 9 803. Therefore, as in In re MannKind, it would be “absurd” to suggest that management did not 10 know about the issues with their flagship product that jeopardized its FDA approval and such 11 allegedly blatant manipulation and misrepresentation in order to save it. And like In re 12 MannKind, an inference of scienter exists “based on the falsity of the statements and Defendants' 13 access to information contradicting those statements.” In re MannKind, 835 F. Supp. 2d at 815. 14 The fact that Conterno and Eisner joined after the NDA submission is irrelevant if their statements 15 were made knowing that the data was manipulated, even if they did not participate in the 16 manipulation themselves. Therefore, both the second and third exceptions apply. 17 Because of the application of the core operations theory, there is an additional basis for a 18 strong inference of scienter for each Individual Defendant. As such, Plaintiffs sufficiently pleaded 19 scienter for all Defendants. 20 V. CONCLUSION 21 For the foregoing reasons, the Court generally DENIES Defendants’ motion to dismiss 22 except the following statements for failure to lack falsity: 23 • Statements regarding the noninferiority margin (Statements # 9, 19, 20, 29, 32, 38, 24 43, 45, and 84) fail to allege falsity to the extent that the CAC alleges that there was 25 an agreement with the FDA but survive to the extent that data was manipulated to 26 conform to those specific margins. Statements # 32, 38, 45, and 84 also survive to 27 the extent they discuss clinical data. 1 impression of the pre-NDA meeting and overall confidence in their NDA 2 submission as opinions that are not actionable. Statements #5 and 34 survive to the 3 extent they discuss clinical data. 4 This order disposes of Docket Nos. 106, 107, and 109. 5 6 IT IS SO ORDERED. 7 8 Dated: July 15, 2022 9 10 ______________________________________ EDWARD M. CHEN 11 United States District Judge 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27